_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,baselinedec,e1,e2,rel-type,sent_id,sentence,term1,term2
724919625,5/22/2015 10:36:44,1641189092,5/22/2015 10:36:31,false,elite,1,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],treatment,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:37:51,1641189913,5/22/2015 10:37:31,false,neodev,1,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treat,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:40:35,1641191574,5/22/2015 10:40:17,false,instagc,1,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],treat,n/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:41:57,1641192481,5/22/2015 10:41:42,false,instagc,1,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],treat,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:46:27,1641195397,5/22/2015 10:46:02,false,prodege,1,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],to treat,N/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:46:55,1641195631,5/22/2015 10:46:40,false,elite,1,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],treatment,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:47:10,1641195782,5/22/2015 10:46:04,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],to treat,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:49:18,1641196904,5/22/2015 10:49:04,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treat,n/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:57:41,1641202089,5/22/2015 10:57:10,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",Acne exacerbation may occur in the early weeks of treatment Slow onset of clinical improvement;,n/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 10:58:59,1641202815,5/22/2015 10:58:26,false,neodev,1,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treat,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 11:25:02,1641218489,5/22/2015 11:24:33,false,neodev,1,29579905,GBR,"","",5.152.206.71,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treatment of treat,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 11:25:50,1641218956,5/22/2015 11:25:33,false,clixsense,1,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],PSORIASIS,N/A,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 12:41:23,1641265761,5/22/2015 12:39:19,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],TAZAROTENE available to treat PSORIASIS,na,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 12:45:23,1641268176,5/22/2015 12:45:02,false,clixsense,1,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treat,n/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919625,5/22/2015 12:49:57,1641270761,5/22/2015 12:49:33,false,clixsense,1,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],to treat,n/a,181,97,-1,189,107,TWrex-cause,800769-FS1,Acne exacerbation may occur in the early weeks of treatment  Slow onset of clinical improvement; TAZAROTENE gel and cream formulations are available in 0.05% concentration to treat PSORIASIS,PSORIASIS,TAZAROTENE
724919626,5/22/2015 08:35:14,1641125456,5/22/2015 08:34:52,false,instagc,1,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],Treatment,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 08:35:35,1641125612,5/22/2015 08:34:59,false,prodege,1,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],Treatment for,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 08:37:07,1641126308,5/22/2015 08:36:52,false,instagc,1,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],Treatment,n/a,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 08:40:48,1641128045,5/22/2015 08:39:29,false,clixsense,1,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","BUPROPION plus SSRI TCA plus SSRI, carefully monitoring TCA levels Mirtazapine plus SSRI Adding an agent not typically used for depression ('augmentation' therapy): Lithium Liothyronine Risperidone Pindolol Buspirone Adding psychotherapy See table Drug Treatment for DEPRESSION...",n/a,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:06:11,1641140532,5/22/2015 09:05:55,false,cointasker,1,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],Treatment,-,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:18:05,1641146545,5/22/2015 09:17:32,false,clixsense,1,28457001,CAN,ON,North Bay,24.204.202.220,[OTHER],[OTHER],not typically used for,not used,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:19:06,1641147126,5/22/2015 09:17:36,false,prodege,1,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],used,NA,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:33:51,1641154398,5/22/2015 09:32:58,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Drug Treatment for,n/a,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:39:38,1641157080,5/22/2015 09:38:54,false,clixsense,1,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"BUPROPION Treatment for DEPRE<span id=""transmark""></span>SSION...",n/a,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:44:50,1641159920,5/22/2015 09:44:32,false,elite,1,31501118,USA,IL,Chicago,158.255.213.24,[OTHER],[OTHER],for,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 09:56:14,1641165623,5/22/2015 09:56:00,false,elite,1,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],Treatment,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 10:06:21,1641171517,5/22/2015 10:06:05,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],('augmentation' therapy):,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 10:06:25,1641171527,5/22/2015 10:05:45,false,neodev,1,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]",an Drug,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 10:06:53,1641171807,5/22/2015 10:06:37,false,elite,1,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],psychotherapy,N/A,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919626,5/22/2015 10:09:48,1641173516,5/22/2015 10:08:51,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,none specified.,290,2,-1,299,11,TWrex-cause,800805-FS1,"— BUPROPION plus SSRI — TCA plus SSRI, carefully monitoring TCA levels — Mirtazapine plus SSRI ◊ Adding an agent not typically used for depression ('augmentation' therapy): — Lithium — Liothyronine — Risperidone — Pindolol — Buspirone ◊ Adding psychotherapy • See table  Drug Treatment for DEPRESSION...",DEPRESSION,BUPROPION
724919627,5/22/2015 10:48:08,1641196303,5/22/2015 10:47:29,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with either,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 10:50:46,1641197848,5/22/2015 10:50:33,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],impact,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 10:53:17,1641199505,5/22/2015 10:52:52,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[IS_A],[IS_A],INFECTION with either INFLUENZA A OR B virus.,N/a,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 11:05:09,1641206626,5/22/2015 11:04:40,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],These agents have impact on duration of INFECTION with either INFLUENZA A OR B virus.,n/a,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 11:08:12,1641208403,5/22/2015 11:07:33,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",an of with,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 11:38:46,1641226797,5/22/2015 11:35:51,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[CAUSES],[CAUSES],INFECTION,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 11:41:50,1641228536,5/22/2015 11:41:27,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A] [PART_OF] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",an of with OR,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 12:56:17,1641274650,5/22/2015 12:55:41,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INFECTION with either INFLUENZA A OR B virus.,na,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:08:49,1641282454,5/22/2015 13:08:16,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[IS_A],[IS_A],with either,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:15:29,1641286969,5/22/2015 13:15:04,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],virus.,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:20:10,1641290161,5/22/2015 13:19:02,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],duration of with,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:20:53,1641290603,5/22/2015 13:19:08,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[IS_A],[IS_A],with either,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:23:56,1641292735,5/22/2015 13:22:18,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [NONE],"[CAUSES]
[NONE]",duration of,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:25:36,1641293835,5/22/2015 13:25:09,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",duration of INFECTION with,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919627,5/22/2015 13:25:48,1641294016,5/22/2015 13:24:56,false,neodev,1,31329809,USA,OH,Columbus,64.79.65.23,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",an of with OR,N/A,47,69,1,55,85,TWrex-cause,812070-FS1,These agents have an impact on the duration of INFECTION with either INFLUENZA A OR B virus.,INFECTION,INFLUENZA A OR B
724919628,5/22/2015 10:22:53,1641180724,5/22/2015 10:22:37,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[PART_OF],[PART_OF],ingredient,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:31:47,1641186018,5/22/2015 10:31:19,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",or of or,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:31:52,1641186060,5/22/2015 10:31:37,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[PART_OF],[PART_OF],Containing,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:32:29,1641186495,5/22/2015 10:31:59,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[CAUSES],[CAUSES],to any ingredient in the vaccine,n/a,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:33:06,1641186828,5/22/2015 10:32:08,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[SIDE_EFFECT],[SIDE_EFFECT],to any ingredient,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:33:26,1641187058,5/22/2015 10:31:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PREVENTS],[PREVENTS],vaccine,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:34:34,1641187706,5/22/2015 10:34:11,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[PREVENTS],[PREVENTS],the vaccine,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:34:58,1641188030,5/22/2015 10:33:12,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[SIDE_EFFECT],[SIDE_EFFECT],to any ingredient in the vaccine,na,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:38:41,1641190393,5/22/2015 10:38:05,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],"to any ingredient in the vaccine (e.g., NEOMYCIN",N/a,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:42:15,1641192664,5/22/2015 10:42:01,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[PART_OF],[PART_OF],ingredient,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:45:09,1641194513,5/22/2015 10:44:23,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],in,n/a,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:48:34,1641196556,5/22/2015 10:47:51,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",or of or,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 10:49:26,1641196994,5/22/2015 10:48:47,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],Fixed combination Vaccine Containing DTaP and IPV SEVERE ALLERGIC REACTION to any ingredient in the vaccine,n/a,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 11:09:16,1641209024,5/22/2015 11:07:28,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[SIDE_EFFECT],[SIDE_EFFECT],"to any ingredient (e.g.,",It states that the symptom may be caused by one of the ingredients,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919628,5/22/2015 11:16:21,1641213461,5/22/2015 11:15:45,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",or of or,N/A,79,164,-1,102,172,TWrex-cause,803086-FS1,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
724919629,5/22/2015 08:37:09,1641126306,5/22/2015 08:36:53,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],Treatment of,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 08:37:48,1641126649,5/22/2015 08:37:28,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],Treatment of,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 08:38:21,1641126863,5/22/2015 08:38:06,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],Treatment,n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 08:44:32,1641129584,5/22/2015 08:43:59,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS],[TREATS],Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.,n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:07:52,1641141370,5/22/2015 09:07:36,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],Treatment,-,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:19:11,1641147176,5/22/2015 09:19:02,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],Treatment,n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:24:51,1641149999,5/22/2015 09:24:29,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],Treatment,NA,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:39:09,1641156846,5/22/2015 09:38:18,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],Treatment with combination,n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:42:57,1641159033,5/22/2015 09:42:24,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"Treatment of CRYPTOCOCCAL MENINGITIS with AMPHOTERICIN <span id=""transmark""></span>B",n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:46:06,1641160479,5/22/2015 09:45:51,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combination,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 09:57:34,1641166476,5/22/2015 09:57:22,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combination,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 10:08:02,1641172544,5/22/2015 10:07:52,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 10:09:40,1641173437,5/22/2015 10:09:11,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with with,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 10:11:11,1641174228,5/22/2015 10:10:47,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],Treatment of,N/A,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919629,5/22/2015 10:12:56,1641175315,5/22/2015 10:12:08,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],Treatment of,n/a,52,93,-1,74,107,TWrex-cause,800370-FS1,"Dismukes WE, Cloud G, Gallis HA et al. Treatment of CRYPTOCOCCAL MENINGITIS with combination AMPHOTERICIN B and flucytosine for four as compared with six weeks.",CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
724919630,5/22/2015 10:45:14,1641194587,5/22/2015 10:44:47,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",An of with of,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 10:47:04,1641195687,5/22/2015 10:46:39,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],effective treatments,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 10:50:19,1641197600,5/22/2015 10:50:03,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],treatments,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 10:52:34,1641199073,5/22/2015 10:52:12,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],effective treatments for,N/a,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 11:04:19,1641206111,5/22/2015 11:03:42,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES,n/a,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 11:06:56,1641207681,5/22/2015 11:06:09,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",of treatment of treatments with,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 11:34:33,1641224256,5/22/2015 11:33:16,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],SCABIES,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 11:39:20,1641227083,5/22/2015 11:38:29,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[PART_OF] [TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",of treatment of with of,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 12:54:23,1641273419,5/22/2015 12:53:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],LINDANE 1% effective treatments for SCABIES,na,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:07:52,1641281781,5/22/2015 13:07:30,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],effective,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:09:27,1641282845,5/22/2015 13:09:18,false,neodev,1,31726043,USA,VA,Manassas,207.244.77.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"children,",cdf,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:13:32,1641285631,5/22/2015 13:12:59,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],treatments for,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:17:38,1641288430,5/22/2015 13:16:25,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatments,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:18:42,1641289176,5/22/2015 13:18:02,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],treatments,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919630,5/22/2015 13:20:40,1641290452,5/22/2015 13:18:42,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",effective treatments for,N/A,151,87,-1,157,97,TWrex-cause,800373-FS1,"• An extensive review of medical literature on the treatment of scabies concluded that LINDANE 1% and permethrin 5% were both effective treatments for SCABIES but that lindane should be used with extreme caution, especially in infants, young children, pregnant females, and lactating women because of possible neurotoxicity ( 46.",SCABIES,LINDANE 1%
724919631,5/22/2015 08:39:09,1641127186,5/22/2015 08:38:36,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],compared with,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 08:40:11,1641127802,5/22/2015 08:39:49,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],for simultaneous primary prophylaxis,n/a,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 08:49:49,1641132188,5/22/2015 08:48:34,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.,n/a,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 08:55:57,1641135217,5/22/2015 08:55:28,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[PREVENTS],[PREVENTS],primary prophylaxis,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:10:19,1641142599,5/22/2015 09:09:24,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[OTHER],[OTHER],compared,-,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:20:28,1641147784,5/22/2015 09:20:10,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[PREVENTS],[PREVENTS],prophylaxis,n/a,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:32:34,1641153726,5/22/2015 09:30:42,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SYMPTOM],[SYMPTOM],infected,NA,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:47:46,1641161351,5/22/2015 09:46:49,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE for TOXOPLASMOSIS in H<span id=""transmark""></span>IV.",n/a,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:48:12,1641161530,5/22/2015 09:47:54,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],pyrimethamine,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 09:58:56,1641167290,5/22/2015 09:58:40,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],pneumocystis pneumonia,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 10:09:10,1641173113,5/22/2015 10:08:59,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[MANIFESTATION],[MANIFESTATION],pneumocystis,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 10:13:20,1641175461,5/22/2015 10:12:39,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [ASSOCIATED_WITH] [PART_OF],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",TRIMETHOPRIM with of with,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 10:17:16,1641177526,5/22/2015 10:15:19,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,just a study,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 10:17:30,1641177622,5/22/2015 10:17:11,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[CAUSES],[CAUSES],infected,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919631,5/22/2015 10:17:51,1641177757,5/22/2015 10:16:50,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[PREVENTS],[PREVENTS],prophylaxis of,N/A,192,42,-1,204,84,TWrex-cause,800011-FS1,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
724919632,5/22/2015 13:36:32,1641300417,5/22/2015 13:34:03,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[SYMPTOM],[SYMPTOM],reduction when given to patients with,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 13:38:14,1641301640,5/22/2015 13:37:28,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",reduction in bone turnover and BONE PAIN when given to patients with,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 13:47:15,1641306910,5/22/2015 13:45:52,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],reduction when given,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:07:57,1641310486,5/22/2015 14:06:50,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",reduction in,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:18:16,1641317445,5/22/2015 14:17:37,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],when given to patients with,n,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:36:42,1641328632,5/22/2015 14:36:18,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[PART_OF],[PART_OF],with,n/a,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:39:09,1641330177,5/22/2015 14:37:31,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BONE PAIN patients with PAGET'S DISEASE OF BONE.,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:40:36,1641330964,5/22/2015 14:40:09,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],double blind trials,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:40:55,1641331170,5/22/2015 14:39:46,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SIDE_EFFECT],[SIDE_EFFECT],when given to patients with,n/a,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:41:38,1641331545,5/22/2015 14:41:07,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],given,n/a,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:42:25,1641331988,5/22/2015 14:41:33,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[PREVENTS],[PREVENTS],"results in reduction in bone turnover markers, and BONE PAIN",n/a,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:43:41,1641332939,5/22/2015 14:43:07,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],given,none,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:53:29,1641338575,5/22/2015 14:53:05,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[SYMPTOM],[SYMPTOM],when given to patients with,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:56:41,1641340797,5/22/2015 14:55:51,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[SYMPTOM],[SYMPTOM],reduction in,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919632,5/22/2015 14:59:02,1641342471,5/22/2015 14:58:41,false,neodev,1,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],results in reduction,N/A,186,224,1,194,247,TWrex-cause,813047-FS1,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
724919633,5/22/2015 08:45:18,1641130025,5/22/2015 08:45:06,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[CAUSES],[CAUSES],caused by,n/a,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 08:45:21,1641130034,5/22/2015 08:45:04,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[CAUSES],[CAUSES],caused by,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 09:04:50,1641139957,5/22/2015 09:04:29,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],caused by,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 09:10:10,1641142493,5/22/2015 09:09:44,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[CAUSES],[CAUSES],Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,n/a,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 09:16:55,1641145831,5/22/2015 09:16:43,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[CAUSES],[CAUSES],caused,-,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 09:51:02,1641162942,5/22/2015 09:49:51,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[CAUSES],[CAUSES],caused,NA,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 09:53:04,1641164086,5/22/2015 09:52:53,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],caused,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:03:03,1641169515,5/22/2015 10:02:17,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[CAUSES],[CAUSES],"COLDS caused by VIR<span id=""transmark""></span>USES",n/a,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:03:13,1641169598,5/22/2015 10:02:58,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],caused,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:14:58,1641176494,5/22/2015 10:14:45,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],caused,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:21:35,1641179904,5/22/2015 10:21:24,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[CAUSES],[CAUSES],caused,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:23:42,1641181182,5/22/2015 10:23:11,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[IS_A]",a caused by,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:29:29,1641184672,5/22/2015 10:29:05,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],caused,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:30:28,1641185231,5/22/2015 10:29:54,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],caused by,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919633,5/22/2015 10:30:38,1641185378,5/22/2015 10:29:40,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is indistinguishable,N/A,76,98,1,80,105,TWrex-cause,810572-FS1,Infections produce a typical coryzal illness that is indistinguishable from COLDS caused by other VIRUSES,COLDS,VIRUSES
724919634,5/22/2015 08:43:52,1641129319,5/22/2015 08:43:37,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],Long term treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 08:44:21,1641129511,5/22/2015 08:44:03,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treatment,n/a,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:03:22,1641139052,5/22/2015 09:03:04,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],treatment with,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:07:12,1641140983,5/22/2015 09:06:40,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS],[TREATS],Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,n/a,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:15:50,1641145324,5/22/2015 09:15:35,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treatment,-,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:46:05,1641160476,5/22/2015 09:44:59,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:52:23,1641163698,5/22/2015 09:52:08,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 09:58:52,1641167220,5/22/2015 09:58:02,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPH<span id=""transmark""></span>AGITIS:",n/a,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:02:26,1641169219,5/22/2015 10:02:07,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:14:16,1641176107,5/22/2015 10:14:04,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:20:49,1641179479,5/22/2015 10:20:37,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:21:48,1641180055,5/22/2015 10:21:19,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:28:06,1641183914,5/22/2015 10:27:51,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],Long term treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:28:20,1641183963,5/22/2015 10:28:02,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],treatment,N/A,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919634,5/22/2015 10:29:31,1641184682,5/22/2015 10:28:22,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treatment,n/a,40,25,-1,68,35,TWrex-cause,800893-FS1,Long term treatment with OMEPRAZOLE for REFRACTORY REFLUX ESOPHAGITIS: efficacy and safety.,REFRACTORY REFLUX ESOPHAGITIS,OMEPRAZOLE
724919635,5/22/2015 13:32:52,1641298261,5/22/2015 13:32:12,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[PREVENTS],[PREVENTS],percutaneous coronary intervention,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 13:36:42,1641300575,5/22/2015 13:36:16,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",compared randomised controlled trial.,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 13:36:55,1641300686,5/22/2015 13:36:18,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled trial.,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 13:44:26,1641305256,5/22/2015 13:43:14,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],in patients undergoing,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 13:51:44,1641309403,5/22/2015 13:50:57,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",compared with,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:17:12,1641316822,5/22/2015 14:16:36,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",undergoing percutaneous coronary intervention,n,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:35:31,1641327991,5/22/2015 14:34:54,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[PART_OF],[PART_OF],for,n/a,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:36:35,1641328577,5/22/2015 14:35:26,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],CLOPIDOGREL in patients undergoing coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:38:43,1641329919,5/22/2015 14:36:34,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[NONE],[NONE],n/a,"Not really sure, the beginning of the sentence is missing",88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:39:53,1641330596,5/22/2015 14:39:35,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],intervention,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:40:25,1641330873,5/22/2015 14:39:56,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],undergoing,n/a,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:40:24,1641330883,5/22/2015 14:39:20,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[OTHER],[OTHER],in patients undergoing percutaneous coronary intervention for ST ELEVATION,n/a,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:41:25,1641331447,5/22/2015 14:40:38,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],patients undergoing,none,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:52:30,1641337965,5/22/2015 14:51:53,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],in patients undergoing,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919635,5/22/2015 14:55:21,1641339866,5/22/2015 14:54:42,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,N/A,88,14,-1,121,25,TWrex-cause,803645-FS1,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
724919636,5/22/2015 10:23:38,1641181135,5/22/2015 10:23:26,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:32:56,1641186759,5/22/2015 10:32:33,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:33:31,1641187109,5/22/2015 10:32:58,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:34:26,1641187623,5/22/2015 10:33:58,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],"therapy,",n/a,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:35:36,1641188388,5/22/2015 10:35:19,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","therapy, prophylaxis.",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:35:49,1641188482,5/22/2015 10:35:02,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:40:27,1641191486,5/22/2015 10:40:06,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],"therapy,",N/a,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:42:53,1641193075,5/22/2015 10:42:43,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:46:08,1641195222,5/22/2015 10:45:51,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],in,n/a,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:50:47,1641197869,5/22/2015 10:50:21,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],"Merz B. Aerosolized PENTAMIDINE promising in PNEUMOCYSTIS therapy, prophylaxis.",n/a,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 10:50:50,1641197914,5/22/2015 10:50:03,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 11:12:29,1641211036,5/22/2015 11:11:27,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[TREATS],[TREATS],"therapy,",The indication is that this drug treats the disease.,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 11:18:08,1641214590,5/22/2015 11:17:40,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],PENTAMIDINE,N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 11:19:29,1641215267,5/22/2015 11:17:28,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS],[TREATS],"therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919636,5/22/2015 11:55:45,1641236607,5/22/2015 11:54:08,false,neodev,1.0,11001780,AUS,07,Elwood,14.201.215.31,[TREATS],[TREATS],"promising therapy,",N/A,46,20,-1,57,31,TWrex-cause,803646-FS1,"Merz B. Aerosolized PENTAMIDINE promising in  PNEUMOCYSTIS  therapy, prophylaxis.",PNEUMOCYSTIS,PENTAMIDINE
724919637,5/22/2015 10:38:01,1641190008,5/22/2015 10:37:43,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[SYMPTOM],[SYMPTOM],Symptoms,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:41:26,1641192143,5/22/2015 10:40:56,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[IS_A]",Symptoms is a Caused by,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:43:15,1641193337,5/22/2015 10:42:57,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],Caused by,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:47:50,1641196147,5/22/2015 10:47:37,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[LOCATION],[LOCATION],skin,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:48:30,1641196517,5/22/2015 10:47:44,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[NONE],[NONE],N/a,Unrelated terms,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:50:07,1641197447,5/22/2015 10:49:54,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],Caused,n/a,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 10:50:44,1641197843,5/22/2015 10:49:30,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(see also,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 11:00:04,1641203428,5/22/2015 10:59:13,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[SYMPTOM],[SYMPTOM],Symptoms and Signs SCHISTOSOME DERMATITIS is a pruritic papular rash,n/a,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 11:01:29,1641204293,5/22/2015 11:00:48,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[SYMPTOM] [IS_A] [CAUSES],"[CAUSES]
[SYMPTOM]
[IS_A]",Symptoms is a Caused by,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 11:27:47,1641219987,5/22/2015 11:27:11,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],papular rash,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 11:35:14,1641224655,5/22/2015 11:34:30,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[SYMPTOM] [IS_A] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[IS_A]",Symptoms is a Caused by,28630436,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 12:46:37,1641268780,5/22/2015 12:45:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SCHISTOSOME DERMATITIS is a rash (see also AVIAN AND ANIMAL SCHISTOSOMES,na,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 12:52:50,1641272322,5/22/2015 12:51:37,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[SYMPTOM],[SYMPTOM],Symptoms and Signs,n/a,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 13:03:24,1641278862,5/22/2015 13:02:19,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CAUSES],[CAUSES],Caused by,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919637,5/22/2015 13:08:43,1641282393,5/22/2015 13:06:40,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],Caused by,N/A,20,140,1,41,169,TWrex-cause,810852-FS1,Symptoms and Signs  SCHISTOSOME DERMATITIS is a pruritic papular rash where the cercariae penetrate the skin (see also Dermatitis Caused by AVIAN AND ANIMAL SCHISTOSOMES below) in previously sensitized people.,SCHISTOSOME DERMATITIS,AVIAN AND ANIMAL SCHISTOSOMES
724919638,5/22/2015 10:23:22,1641181022,5/22/2015 10:23:10,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[LOCATION],[LOCATION],in,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:32:30,1641186522,5/22/2015 10:32:17,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:32:55,1641186745,5/22/2015 10:32:11,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:33:56,1641187359,5/22/2015 10:33:36,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],THERAPY,n/a,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:34:59,1641188035,5/22/2015 10:34:25,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:35:18,1641188209,5/22/2015 10:35:04,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],THERAPY in,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:38:28,1641190276,5/22/2015 10:36:40,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,just a rct,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:40:05,1641191239,5/22/2015 10:39:37,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION,N/a,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:42:41,1641192932,5/22/2015 10:42:30,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:45:50,1641195039,5/22/2015 10:45:33,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],in,n/a,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:49:50,1641197266,5/22/2015 10:49:15,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 10:50:20,1641197601,5/22/2015 10:49:50,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION,n/a,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 11:11:26,1641210399,5/22/2015 11:10:30,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[PART_OF],[PART_OF],in,"It states it is ""in"" which indicates part of.",70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 11:16:59,1641213839,5/22/2015 11:16:28,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS],[TREATS],THERAPY,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919638,5/22/2015 11:17:38,1641214328,5/22/2015 11:16:51,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],MYOCARDIAL INFARCTION,N/A,70,37,-1,99,66,TWrex-cause,803527-FS1,"Hasin Y, Freiman I, Schwarz T et al. INTRAVENOUS VERAPAMIL THERAPY in IMMINENT MYOCARDIAL INFARCTION",IMMINENT MYOCARDIAL INFARCTION,INTRAVENOUS VERAPAMIL THERAPY
724919639,5/22/2015 13:10:23,1641283504,5/22/2015 13:09:04,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],ANAPLASTIC ASTROCYTOMAS characterized by NUCLEAR ATYPIA,na,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:14:19,1641286126,5/22/2015 13:13:45,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[MANIFESTATION],[MANIFESTATION],characterized,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:27:09,1641294968,5/22/2015 13:26:36,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[SYMPTOM],[SYMPTOM],characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:27:20,1641295062,5/22/2015 13:25:42,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[SYMPTOM],[SYMPTOM],characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:28:48,1641295951,5/22/2015 13:28:35,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",are characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:34:45,1641299386,5/22/2015 13:33:18,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:44:26,1641305245,5/22/2015 13:43:46,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SYMPTOM],[SYMPTOM],are characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 13:46:57,1641306735,5/22/2015 13:45:33,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[MANIFESTATION] [NONE],"[MANIFESTATION]
[NONE]",characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:10:04,1641311863,5/22/2015 14:09:39,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:13:36,1641314782,5/22/2015 14:13:14,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[MANIFESTATION],[MANIFESTATION],are characterized by,n/a,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:27:24,1641323137,5/22/2015 14:26:10,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SYMPTOM],[SYMPTOM],characterized by,n/a,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:31:27,1641325533,5/22/2015 14:30:59,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are characterized by,n/a,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:31:31,1641325587,5/22/2015 14:30:52,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[SYMPTOM],[SYMPTOM],characterized by,n/a,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:31:49,1641325732,5/22/2015 14:31:33,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[MANIFESTATION],[MANIFESTATION],characterized by,N/A,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919639,5/22/2015 14:36:03,1641328226,5/22/2015 14:35:37,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],characterized,none,45,0,1,58,23,TWrex-cause,812912-FS1,ANAPLASTIC ASTROCYTOMAS are characterized by NUCLEAR ATYPIA and mitotic activity.,NUCLEAR ATYPIA,ANAPLASTIC ASTROCYTOMAS
724919640,5/22/2015 10:23:07,1641180895,5/22/2015 10:22:55,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[CAUSES],[CAUSES],caused,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:32:08,1641186232,5/22/2015 10:31:54,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],Treatment,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:32:13,1641186315,5/22/2015 10:31:51,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",Treatment of caused by,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:33:35,1641187150,5/22/2015 10:32:29,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],Treatment of,n/a,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:34:15,1641187483,5/22/2015 10:33:09,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[IS_A],[IS_A],other,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:34:19,1641187531,5/22/2015 10:33:28,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],Streptococcus pneumoniae and other STREPTOCOCCI,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:35:02,1641188089,5/22/2015 10:34:35,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],caused by,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:36:39,1641189028,5/22/2015 10:35:01,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],Treatment of,n/a,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:39:36,1641190956,5/22/2015 10:38:42,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],Treatment of serious infections caused by,N/a,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:42:28,1641192818,5/22/2015 10:42:16,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],Treatment,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:45:32,1641194775,5/22/2015 10:45:11,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:49:12,1641196864,5/22/2015 10:48:38,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [IS_A],"[TREATS]
[IS_A]",Treatment of caused by,N/A`,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 10:49:50,1641197263,5/22/2015 10:49:27,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],Uses Staphylococcal and STREPTOCOCCAL INFECTIONS Treatment of serious infections,n/a,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 11:10:29,1641209799,5/22/2015 11:09:16,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[CAUSES],[CAUSES],caused by,"Directly states ""caused by""",25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919640,5/22/2015 11:16:50,1641213717,5/22/2015 11:15:59,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[CAUSES],[CAUSES],STREPTOCOCCI,N/A,25,158,1,48,170,TWrex-cause,810339-FS1,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
724919641,5/22/2015 08:43:19,1641129104,5/22/2015 08:42:54,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reduces the incidence after coronary artery,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 08:43:44,1641129230,5/22/2015 08:43:22,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[PREVENTS],[PREVENTS],reduces the incidence,n/a,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:02:12,1641138547,5/22/2015 09:01:51,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[PREVENTS],[PREVENTS],reduces incidence,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:04:23,1641139638,5/22/2015 09:03:23,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.,n/a,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:15:16,1641145085,5/22/2015 09:14:59,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],reduces,-,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:44:28,1641159683,5/22/2015 09:43:02,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],reduces,NA,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:51:49,1641163368,5/22/2015 09:51:35,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],reduces,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 09:56:43,1641165943,5/22/2015 09:55:57,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[PREVENTS],[PREVENTS],"ORAL SOTALOL reduces the incidence of ATRIAL FIBR<span id=""transmark""></span>ILLATION",n/a,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:01:45,1641168806,5/22/2015 10:01:31,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],reduces,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:13:46,1641175698,5/22/2015 10:13:34,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],reduces,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:20:21,1641179305,5/22/2015 10:20:01,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],reduces,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:20:29,1641179389,5/22/2015 10:19:59,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:27:31,1641183510,5/22/2015 10:26:15,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",reduces the incidence of,n/a,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:27:33,1641183534,5/22/2015 10:26:49,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],reduces the incidence,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919641,5/22/2015 10:27:59,1641183836,5/22/2015 10:27:28,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[PREVENTS],[PREVENTS],reduces,N/A,106,68,-1,124,80,TWrex-cause,800939-FS1,"1]  Nystrom U, Edvardsson N, Berggren H, Pizzarelli GP, Radegran K. ORAL SOTALOL reduces the incidence of ATRIAL FIBRILLATION after coronary artery bypass surgery.",ATRIAL FIBRILLATION,ORAL SOTALOL
724919642,5/22/2015 08:42:29,1641128736,5/22/2015 08:41:46,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[OTHER],[OTHER],resulting in,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 08:42:57,1641128925,5/22/2015 08:42:39,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resulting in,n/a,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:01:11,1641138067,5/22/2015 09:00:21,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[LOCATION],[LOCATION],INTRAOCULAR,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:01:26,1641138185,5/22/2015 09:00:21,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[LOCATION],[LOCATION],"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",n/a,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:14:33,1641144714,5/22/2015 09:13:58,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SIDE_EFFECT],[SIDE_EFFECT],resulting,-,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:42:36,1641158829,5/22/2015 09:41:02,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],resulting,NA,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:51:19,1641163052,5/22/2015 09:51:04,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[MANIFESTATION],[MANIFESTATION],surface,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 09:54:29,1641164724,5/22/2015 09:53:43,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[OTHER],[OTHER],"LOWERED INTRAOCULAR PRESSURE of the E<span id=""transmark""></span>YE.",n/a,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:01:12,1641168503,5/22/2015 10:00:53,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],surface,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:13:19,1641175449,5/22/2015 10:13:04,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[LOCATION],[LOCATION],surface,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:19:07,1641178703,5/22/2015 10:18:33,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of a of,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:19:44,1641178989,5/22/2015 10:19:31,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[LOCATION],[LOCATION],the surface,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:25:32,1641182351,5/22/2015 10:24:56,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[LOCATION],[LOCATION],on the surface of the,n/a,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:26:41,1641182990,5/22/2015 10:25:44,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[LOCATION],[LOCATION],on the surface of,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919642,5/22/2015 10:26:47,1641183066,5/22/2015 10:26:15,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[LOCATION],[LOCATION],surface of the EYE.,N/A,171,76,-1,173,104,TWrex-cause,802161-FS1,"This allows fluid to flow out of the eye through this opening, resulting in LOWERED INTRAOCULAR PRESSURE and the formation of a bleb or fluid bubble on the surface of the EYE.",EYE,LOWERED INTRAOCULAR PRESSURE
724919643,5/22/2015 13:38:39,1641301869,5/22/2015 13:37:28,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[IS_A],[IS_A],SWEAT NONINTACT SKIN,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 13:38:57,1641302061,5/22/2015 13:38:34,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[LOCATION],[LOCATION],(except SWEAT NONINTACT,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 13:50:07,1641308544,5/22/2015 13:48:45,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(except SWEAT NONINTACT SKIN,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:10:33,1641312499,5/22/2015 14:08:39,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[PART_OF],[PART_OF],and are,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:19:11,1641318077,5/22/2015 14:18:34,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",These precautions,n,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:37:33,1641329135,5/22/2015 14:36:58,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:40:46,1641331069,5/22/2015 14:39:52,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],SWEAT NONINTACT SKIN,that is the full name,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:41:17,1641331354,5/22/2015 14:40:49,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],SWEAT NONINTACT SKIN,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:43:09,1641332524,5/22/2015 14:42:14,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],successful,n/a,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:43:49,1641332987,5/22/2015 14:41:32,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[NONE],[NONE],n/a,"it seems to be one term""SWEAT NONINTACT SKIN"" , it belongs together",193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:44:10,1641333144,5/22/2015 14:43:10,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[OTHER],[OTHER],(except SWEAT NONINTACT SKIN and,n/a,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:45:29,1641333863,5/22/2015 14:44:15,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],strategy for successful,none,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:55:18,1641339836,5/22/2015 14:54:18,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[NONE],[NONE],N/A,"They are 2 different examples, not related to each other.",193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:57:33,1641341443,5/22/2015 14:57:10,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SWEAT NONINTACT SKIN,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919643,5/22/2015 14:58:21,1641342031,5/22/2015 14:58:02,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],SWEAT NONINTACT SKIN,N/A,193,187,-1,206,192,TWrex-cause,802282-FS1,"These precautions (e.g., handwashing and wearing personal protective equipment such as gloves, mask, eye protection, gown) apply to blood, all body fluids, secretions, excretions (except SWEAT NONINTACT SKIN and mucous membranes of all patients and are the primary strategy for successful nosocomial infection control.",NONINTACT SKIN,SWEAT
724919644,5/22/2015 10:47:29,1641195987,5/22/2015 10:47:04,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],therapy for treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 10:50:32,1641197692,5/22/2015 10:50:21,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 10:52:51,1641199186,5/22/2015 10:52:35,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],therapy for treating,N/a,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 11:04:39,1641206285,5/22/2015 11:04:20,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],alGLUCOSAMINE therapy for treating OSTEOARTHRITIS,n/a,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 11:07:29,1641208005,5/22/2015 11:06:59,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS],[TREATS],therapy,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 11:35:50,1641225058,5/22/2015 11:34:34,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],OSTEOARTHRITIS,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 11:41:25,1641228262,5/22/2015 11:39:55,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS],[TREATS],therapy treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 12:55:40,1641274233,5/22/2015 12:54:24,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],alGLUCOSAMINE therapy for treating OSTEOARTHRITIS,na,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:08:15,1641282113,5/22/2015 13:07:52,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],for treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:09:37,1641282967,5/22/2015 13:09:29,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[PREVENTS],[PREVENTS],et,ddd,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:15:04,1641286606,5/22/2015 13:13:33,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],for treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:18:59,1641289327,5/22/2015 13:17:39,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:19:07,1641289425,5/22/2015 13:18:44,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:22:16,1641291543,5/22/2015 13:20:42,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919644,5/22/2015 13:26:01,1641294139,5/22/2015 13:25:49,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],therapy for treating,N/A,112,79,-1,125,90,TWrex-cause,803494-FS1,"1]  Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et alGLUCOSAMINE therapy for treating OSTEOARTHRITIS",OSTEOARTHRITIS,GLUCOSAMINE
724919645,5/22/2015 08:36:18,1641125900,5/22/2015 08:36:03,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],treatment of,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 08:37:05,1641126285,5/22/2015 08:36:36,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],treatment of,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 08:37:48,1641126648,5/22/2015 08:37:36,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treatment,n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 08:43:14,1641129068,5/22/2015 08:42:35,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS],[TREATS],Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.,n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:07:19,1641141099,5/22/2015 09:07:03,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treatment,-,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:18:48,1641146989,5/22/2015 09:18:35,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],the treatment,n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:24:11,1641149639,5/22/2015 09:21:59,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:37:44,1641156207,5/22/2015 09:37:24,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],for the treatment of,n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:41:51,1641158308,5/22/2015 09:41:02,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"PERMETHRIN 5% CREAM (ELIMITE) treatment of SC<span id=""transmark""></span>ABIES",n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:45:35,1641160252,5/22/2015 09:45:21,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 09:57:04,1641166134,5/22/2015 09:56:51,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 10:07:34,1641172312,5/22/2015 10:07:23,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treatment,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 10:08:33,1641172783,5/22/2015 10:08:05,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 10:09:30,1641173335,5/22/2015 10:08:45,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],treatment of,N/A,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919645,5/22/2015 10:11:35,1641174496,5/22/2015 10:11:14,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treatment of,n/a,136,85,-1,142,114,TWrex-cause,803495-FS1,"Taplin D, Meinking TL, Chen JA et al. Comparison of crotamiton 10% cream (Eurax) and PERMETHRIN 5% CREAM (ELIMITE) for the treatment of SCABIES in children.",SCABIES,PERMETHRIN 5% CREAM (ELIMITE)
724919646,5/22/2015 10:36:12,1641188736,5/22/2015 10:35:58,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[SIDE_EFFECT],[SIDE_EFFECT],affected,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:37:01,1641189392,5/22/2015 10:36:30,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [PART_OF] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[IS_A]
[PART_OF]",by of is a symptom,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:39:21,1641190814,5/22/2015 10:38:46,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[LOCATION],[LOCATION],affected by,n/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:40:48,1641191647,5/22/2015 10:40:32,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[LOCATION],[LOCATION],affected by,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:44:23,1641194050,5/22/2015 10:43:35,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],BONE affected by PAGET'S DISEASE,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:45:30,1641194733,5/22/2015 10:45:00,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[LOCATION],[LOCATION],affected by,N/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:46:20,1641195342,5/22/2015 10:46:10,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[SIDE_EFFECT],[SIDE_EFFECT],affected,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:48:46,1641196655,5/22/2015 10:48:27,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[LOCATION],[LOCATION],affected,n/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:56:27,1641201332,5/22/2015 10:56:07,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],"BONE affected by PAGET'S DISEASE can enlarge,",n/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 10:57:44,1641202127,5/22/2015 10:57:15,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [PART_OF] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[IS_A]
[PART_OF]",by of is a symptom,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 11:23:55,1641217768,5/22/2015 11:23:30,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[PART_OF]",by of is a symptom,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 11:24:25,1641218156,5/22/2015 11:23:33,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],deformity,N/A,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 12:38:34,1641264036,5/22/2015 12:37:13,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],BONE affected by PAGET'S DISEASE,na,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 12:44:04,1641267372,5/22/2015 12:43:37,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affected by,n/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919646,5/22/2015 12:49:32,1641270449,5/22/2015 12:48:04,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[OTHER],[OTHER],affected by,n/a,12,29,-1,15,44,TWrex-cause,802286-FS1,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
724919647,5/22/2015 10:25:14,1641182138,5/22/2015 10:25:00,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:35:27,1641188272,5/22/2015 10:35:04,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:35:46,1641188455,5/22/2015 10:35:25,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS],[TREATS],TRIMETHOPRIM therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:37:34,1641189724,5/22/2015 10:37:12,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],in the therapy of,n/a,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:39:55,1641191127,5/22/2015 10:39:37,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],therapy of,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:41:29,1641192182,5/22/2015 10:40:56,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],therapy of,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:43:40,1641193579,5/22/2015 10:43:18,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],in the therapy of,N/a,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:45:37,1641194829,5/22/2015 10:45:25,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:47:47,1641196118,5/22/2015 10:47:29,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],therapy,n/a,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:54:37,1641200189,5/22/2015 10:53:59,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],"Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",n/a,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 10:55:36,1641200763,5/22/2015 10:55:00,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS],[TREATS],TRIMETHOPRIM therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 11:22:36,1641216986,5/22/2015 11:22:12,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],TRACT INFECTIONS,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 11:22:44,1641217091,5/22/2015 11:22:24,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS],[TREATS],TRIMETHOPRIM therapy,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 11:59:20,1641238575,5/22/2015 11:59:10,false,prodege,1.0,12656479,CAN,NB,Fredericton,198.164.157.90,[TREATS],[TREATS],versus,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919647,5/22/2015 12:16:29,1641249097,5/22/2015 12:15:53,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],TRIMETHOPRIM SULFAMETHOXAZOLE in therapy of URINARY TRACT INFECTIONS,N/A,138,56,-1,161,85,TWrex-cause,800384-FS1,"Goldstein EJ, Alpert JL, Ginsberg B. Norfloxacin versus TRIMETHOPRIM SULFAMETHOXAZOLE in the therapy of uncomplicated, community acquired URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
724919648,5/22/2015 08:40:08,1641127785,5/22/2015 08:39:54,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 08:40:53,1641128085,5/22/2015 08:40:38,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],therapy,n/a,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 08:51:23,1641133056,5/22/2015 08:50:49,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Combination AZELAIC ACID therapy for ACNE VULGARIS.,n/a,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 08:57:13,1641135885,5/22/2015 08:56:56,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:11:49,1641143231,5/22/2015 09:10:57,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],therapy,-,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:21:02,1641148080,5/22/2015 09:20:54,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],therapy,n/a,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:34:24,1641154610,5/22/2015 09:33:21,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],therapy,NA,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:49:00,1641161868,5/22/2015 09:48:45,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:49:39,1641162245,5/22/2015 09:49:12,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"AZELAIC ACID therapy for ACNE VULG<span id=""transmark""></span>ARIS.",n/a,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 09:59:32,1641167545,5/22/2015 09:59:18,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 10:09:38,1641173432,5/22/2015 10:09:27,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 10:14:20,1641176126,5/22/2015 10:13:58,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 10:18:10,1641177992,5/22/2015 10:17:59,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],therapy,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 10:20:09,1641179241,5/22/2015 10:19:45,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],therapy for,N/A,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919648,5/22/2015 10:21:20,1641179763,5/22/2015 10:21:09,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],therapy for,n/a,48,23,-1,60,35,TWrex-cause,804226-FS1,Webster G: Combination AZELAIC ACID therapy for ACNE VULGARIS.,ACNE VULGARIS,AZELAIC ACID
724919649,5/22/2015 08:40:46,1641128035,5/22/2015 08:40:30,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],primary therapy for,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 08:41:36,1641128435,5/22/2015 08:41:11,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],primary therapy,n/a,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 08:53:17,1641133869,5/22/2015 08:52:10,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[MANIFESTATION],[MANIFESTATION],Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA,n/a,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 08:58:04,1641136385,5/22/2015 08:57:45,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 09:12:17,1641143564,5/22/2015 09:12:05,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],therapy,-,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 09:36:37,1641155669,5/22/2015 09:35:22,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],therapy,NA,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 09:50:17,1641162455,5/22/2015 09:49:52,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 09:50:56,1641162860,5/22/2015 09:50:12,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"CHLORAMBUCIL therapy for CHRONIC LYMPHOC<span id=""transmark""></span>YTIC LEUKEMIA",n/a,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:00:01,1641167743,5/22/2015 09:59:48,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:10:04,1641173616,5/22/2015 10:09:51,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:15:31,1641176793,5/22/2015 10:14:57,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:18:43,1641178382,5/22/2015 10:18:28,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],therapy,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:21:53,1641180129,5/22/2015 10:21:01,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],therapy for,N/A,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:22:39,1641180565,5/22/2015 10:21:58,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],therapy,n/a,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919649,5/22/2015 10:23:04,1641180836,5/22/2015 10:22:42,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],primary therapy for,n/a,103,67,-1,130,79,TWrex-cause,803413-FS1,"Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
724919650,5/22/2015 10:35:41,1641188404,5/22/2015 10:35:28,false,elite,1,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],produce,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:36:06,1641188647,5/22/2015 10:35:50,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:38:02,1641190032,5/22/2015 10:37:34,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",able to produce,n/a,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:40:12,1641191313,5/22/2015 10:39:56,false,instagc,1,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],able to produce,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:42:28,1641192817,5/22/2015 10:41:31,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],able to produce,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:44:33,1641194143,5/22/2015 10:43:41,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],are able to produce,N/a,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:45:53,1641195057,5/22/2015 10:45:39,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:48:09,1641196306,5/22/2015 10:47:47,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],produce,n/a,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:55:07,1641200531,5/22/2015 10:54:38,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER,n/a,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 10:56:35,1641201434,5/22/2015 10:55:41,false,neodev,1,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 11:23:04,1641217318,5/22/2015 11:22:47,false,neodev,1,29579905,GBR,"","",5.152.206.71,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 11:23:10,1641217351,5/22/2015 11:22:36,false,clixsense,1,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],severe disease,N/A,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 12:23:05,1641253171,5/22/2015 12:22:56,false,neodev,1,31789301,NLD,"","",146.185.183.119,[NONE],[NONE],no,no,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 12:33:04,1641260460,5/22/2015 12:32:12,false,elite,1,31526431,USA,CA,Elk Grove,67.166.135.122,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919650,5/22/2015 12:35:49,1641262337,5/22/2015 12:34:01,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],DENGUE VIRUSES produce DENGUE HEMORRHAGIC FEVER,na,53,18,1,76,32,TWrex-cause,811399-FS1,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
724919651,5/22/2015 13:27:29,1641295160,5/22/2015 13:27:10,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[MANIFESTATION],[MANIFESTATION],(including,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 13:28:43,1641295890,5/22/2015 13:27:21,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[IS_A],[IS_A],(including,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 13:29:02,1641296097,5/22/2015 13:28:49,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",(including,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 13:35:59,1641300106,5/22/2015 13:34:47,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[SIDE_EFFECT],[SIDE_EFFECT],may result in,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 13:45:40,1641305904,5/22/2015 13:44:28,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",may result,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 13:51:28,1641309280,5/22/2015 13:50:51,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [SIDE_EFFECT] [NONE],"[CAUSES]
[SIDE_EFFECT]
[NONE]",may result in,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:11:28,1641313328,5/22/2015 14:10:05,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],may result in SEIZURES (including STATUS EPILEPTICUS,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:14:00,1641315044,5/22/2015 14:13:36,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(including,n/a,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:28:11,1641323534,5/22/2015 14:27:25,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[IS_A],[IS_A],(including,n/a,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:31:54,1641325736,5/22/2015 14:31:33,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[PART_OF],[PART_OF],(including,n/a,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:32:03,1641325792,5/22/2015 14:31:50,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[CAUSES],[CAUSES],Rapid dosage reduction,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:32:03,1641325794,5/22/2015 14:31:28,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[PART_OF],[PART_OF],(including STATUS EPILEPTICUS,n/a,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:36:15,1641328337,5/22/2015 14:35:50,false,points4rewards,1,20306700,USA,WA,Bothell,50.125.145.37,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",result,n/a,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:36:29,1641328479,5/22/2015 14:36:05,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CAUSES],[CAUSES],result,none,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919651,5/22/2015 14:37:56,1641329309,5/22/2015 14:37:33,false,sharecashgpt,1,28627999,CAN,ON,Sudbury,66.103.55.12,[CAUSES],[CAUSES],may result in,N/A,62,82,1,69,100,TWrex-cause,813855-FS1,"Rapid dosage reduction or abrupt discontinuance may result in SEIZURES (including STATUS EPILEPTICUS  102 ,   103   delirium,  102 ,   104   or withdrawal symptoms.",SEIZURES,STATUS EPILEPTICUS
724919652,5/22/2015 08:42:53,1641128908,5/22/2015 08:42:31,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[PART_OF],[PART_OF],and other,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 08:43:19,1641129118,5/22/2015 08:42:58,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and other symptoms,n/a,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:01:49,1641138365,5/22/2015 09:01:12,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[SYMPTOM],[SYMPTOM],symptoms,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:03:22,1641139057,5/22/2015 09:01:28,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[SYMPTOM] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","Importance of advising patients receiving prazosin for PTSD + that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",n/a,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:14:58,1641144949,5/22/2015 09:14:34,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[IS_A],[IS_A],and other,-,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:43:01,1641159089,5/22/2015 09:42:37,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],reduce,NA,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:51:34,1641163246,5/22/2015 09:51:21,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SYMPTOM],[SYMPTOM],symptoms,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 09:55:55,1641165415,5/22/2015 09:54:31,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[SYMPTOM] [ASSOCIATED_WITH] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]","ANXIETY and other PTSD related sy<span id=""transmark""></span>mptoms",n/a,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:01:28,1641168722,5/22/2015 10:01:14,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],symptoms;,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:13:32,1641175573,5/22/2015 10:13:20,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[SYMPTOM],[SYMPTOM],symptoms,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:19:56,1641179106,5/22/2015 10:19:10,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[IS_A]
[PART_OF]",of drug symptoms; symptoms is,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:19:59,1641179129,5/22/2015 10:19:47,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[SYMPTOM],[SYMPTOM],symptoms,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:26:15,1641182717,5/22/2015 10:25:34,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[SYMPTOM],[SYMPTOM],related symptoms,n/a,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:27:25,1641183466,5/22/2015 10:26:44,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],symptoms,N/A,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919652,5/22/2015 10:28:19,1641183961,5/22/2015 10:26:20,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other,n/a,214,70,1,220,74,TWrex-cause,810468-FS1,"101 ,   218 •  Importance of advising patients receiving prazosin for PTSD   +    that the drug may help reduce nightmares and improve sleep and other symptoms; however, it does not cure PTSD and their nightmares, ANXIETY and other PTSD related symptoms may return if therapy is stopped.",ANXIETY,PTSD
724919653,5/22/2015 08:39:53,1641127664,5/22/2015 08:39:10,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],blind study in 40 patients with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 08:40:38,1641127990,5/22/2015 08:40:12,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 08:50:49,1641132760,5/22/2015 08:49:49,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",n/a,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 08:56:55,1641135724,5/22/2015 08:55:58,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[MANIFESTATION],[MANIFESTATION],with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:10:56,1641142873,5/22/2015 09:10:20,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SYMPTOM],[SYMPTOM],with,-,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:20:54,1641147982,5/22/2015 09:20:29,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SYMPTOM],[SYMPTOM],in 40 patients,n/a,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:33:20,1641154132,5/22/2015 09:32:35,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],alleviate,NA,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:48:43,1641161777,5/22/2015 09:48:15,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],improve,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:49:11,1641161954,5/22/2015 09:47:47,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"PAIN in POSTTRAUMATIC R<span id=""transmark""></span>SD",n/a,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 09:59:16,1641167452,5/22/2015 09:58:58,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 10:09:25,1641173311,5/22/2015 10:09:12,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 10:13:54,1641175758,5/22/2015 10:13:23,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",a with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 10:17:56,1641177789,5/22/2015 10:17:32,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],improve,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 10:19:41,1641178951,5/22/2015 10:17:54,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[SYMPTOM],[SYMPTOM],alleviate in 40 patients with,N/A,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919653,5/22/2015 10:21:11,1641179623,5/22/2015 10:20:45,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],alleviate,n/a,42,165,1,45,182,TWrex-cause,813736-FS1,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
724919654,5/22/2015 08:41:11,1641128216,5/22/2015 08:40:47,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[OTHER],[OTHER],"randomized, controlled study",N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 08:42:08,1641128649,5/22/2015 08:41:37,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],study,n/a,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 08:54:28,1641134386,5/22/2015 08:53:18,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",n/a,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 08:59:27,1641136987,5/22/2015 08:58:06,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[SYMPTOM],[SYMPTOM],WITH,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 09:12:45,1641143810,5/22/2015 09:12:17,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[OTHER],[OTHER],compared,-,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 09:37:37,1641156175,5/22/2015 09:36:38,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],benefit function,NA,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 09:50:33,1641162645,5/22/2015 09:50:18,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],"randomized,",N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 09:52:09,1641163529,5/22/2015 09:50:58,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"Fluoxe<span id=""transmark""></span>tine ALLEVIATE PAIN AND FATIGUE FEMALE PATIENTS WITH FMS",n/a,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:00:16,1641167903,5/22/2015 10:00:04,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:10:22,1641173827,5/22/2015 10:10:05,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:16:12,1641177056,5/22/2015 10:15:34,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",an of with a,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:18:59,1641178579,5/22/2015 10:18:46,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:23:26,1641181043,5/22/2015 10:21:57,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],Fluoxetine,N/A,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:23:59,1641181392,5/22/2015 10:23:04,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],found to benefit,n/a,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919654,5/22/2015 10:24:10,1641181542,5/22/2015 10:22:41,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],significantly benefit function ALLEVIATE PAIN AND FATIGUE,n/a,99,204,1,124,228,TWrex-cause,812802-FS1,"◊ Fluoxetine alone, at an average dose of 55 mg/d, was found to significantly benefit function and ALLEVIATE PAIN AND FATIGUE as compared with placebo in a double blind randomized, controlled study of 60 FEMALE PATIENTS WITH FMS ( 99.",ALLEVIATE PAIN AND FATIGUE,FEMALE PATIENTS WITH FMS
724919655,5/22/2015 08:38:35,1641126981,5/22/2015 08:38:13,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",may cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 08:39:48,1641127589,5/22/2015 08:39:33,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[CAUSES],[CAUSES],may cause,n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 08:48:33,1641131638,5/22/2015 08:47:35,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]","History Use of prescription, over the counter, and illicit drugs Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 08:55:27,1641134923,5/22/2015 08:54:51,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],may cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:09:23,1641142070,5/22/2015 09:09:09,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[CAUSES],[CAUSES],cause,-,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:20:09,1641147662,5/22/2015 09:19:53,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[CAUSES],[CAUSES],may cause,n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:30:41,1641152891,5/22/2015 09:28:31,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",cause,NA,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:42:57,1641159040,5/22/2015 09:42:33,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[CAUSES],[CAUSES],may cause,n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:46:47,1641160818,5/22/2015 09:45:58,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[SIDE_EFFECT],[SIDE_EFFECT],"Use o<span id=""transmark""></span>f ASPIRIN may cause BLEEDING DIATHESES",n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:47:51,1641161370,5/22/2015 09:47:00,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 09:58:38,1641167112,5/22/2015 09:58:23,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 10:08:58,1641172952,5/22/2015 10:08:45,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 10:12:36,1641175167,5/22/2015 10:12:06,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]","of drugs or drugs, drugs cause",N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 10:15:16,1641176667,5/22/2015 10:14:42,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[CAUSES],[CAUSES],cause,n/a,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919655,5/22/2015 10:16:46,1641177297,5/22/2015 10:14:33,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],may cause,N/A,191,83,1,208,90,TWrex-cause,811559-FS1,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
724919656,5/22/2015 13:08:12,1641282095,5/22/2015 13:07:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"FRACTURE where side of BONE is compressed,",na,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:13:16,1641285501,5/22/2015 13:12:50,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[LOCATION],[LOCATION],structure of,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:25:15,1641293598,5/22/2015 13:24:40,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[LOCATION],[LOCATION],where the structure of one side,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:25:17,1641293626,5/22/2015 13:24:24,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[LOCATION],[LOCATION],the structure of one side,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:28:14,1641295644,5/22/2015 13:27:51,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[LOCATION],[LOCATION],where the structure of one side of the,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:31:48,1641297607,5/22/2015 13:30:42,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[LOCATION],[LOCATION],where,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:42:24,1641304122,5/22/2015 13:41:37,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[LOCATION],[LOCATION],"is compressed,",N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:43:39,1641304709,5/22/2015 13:41:21,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [SIDE_EFFECT] [NONE],"[CAUSES]
[SIDE_EFFECT]
[NONE]",deflects from,N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 13:50:46,1641308912,5/22/2015 13:49:32,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[CAUSES],[CAUSES],"FRACTURE where one side of BONE is compressed,",N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:12:48,1641314243,5/22/2015 14:12:22,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the structure,n/a,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:25:25,1641321770,5/22/2015 14:24:17,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SYMPTOM],[SYMPTOM],where the structure,n/a,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:27:13,1641323051,5/22/2015 14:25:38,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[LOCATION],[LOCATION],structure of one side of,n/a,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:30:29,1641324851,5/22/2015 14:29:40,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[IS_A],[IS_A],where the structure one side,n/a,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:31:12,1641325354,5/22/2015 14:30:58,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[SIDE_EFFECT],[SIDE_EFFECT],"compressed,",N/A,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919656,5/22/2015 14:35:08,1641327731,5/22/2015 14:34:30,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],"compressed,",none,50,2,-1,53,10,TWrex-cause,802729-FS1,"A FRACTURE where the structure of one side of the BONE is compressed, while the opposite side deflects from the growth plate, leaving the cortex intact.",BONE,FRACTURE
724919657,5/22/2015 08:45:57,1641130430,5/22/2015 08:45:47,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treatment,n/a,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 08:46:11,1641130602,5/22/2015 08:46:00,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],treatment of,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 09:06:20,1641140584,5/22/2015 09:06:03,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],treatment of,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 09:12:27,1641143651,5/22/2015 09:11:54,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS],[TREATS],Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.,n/a,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 09:17:39,1641146314,5/22/2015 09:17:28,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treatment,-,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 09:54:08,1641164562,5/22/2015 09:53:55,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 09:54:29,1641164722,5/22/2015 09:53:10,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:04:05,1641170091,5/22/2015 10:03:46,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:06:08,1641171356,5/22/2015 10:05:42,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"TERBINAFINE treatment of TINEA CAPIT<span id=""transmark""></span>IS",n/a,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:15:42,1641176898,5/22/2015 10:15:29,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:22:19,1641180412,5/22/2015 10:22:07,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:25:41,1641182428,5/22/2015 10:25:04,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:30:50,1641185489,5/22/2015 10:30:34,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF],[PART_OF],of,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:31:14,1641185685,5/22/2015 10:30:40,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],the treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919657,5/22/2015 10:31:18,1641185723,5/22/2015 10:30:40,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],treatment,N/A,72,40,-1,84,51,TWrex-cause,804079-FS1,"Rademaker M, Havill S. Griseofulvin and TERBINAFINE in the treatment of TINEA CAPITIS in children.",TINEA CAPITIS,TERBINAFINE
724919658,5/22/2015 08:41:44,1641128466,5/22/2015 08:41:28,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],are effective,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 08:42:38,1641128788,5/22/2015 08:42:23,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],effective for,n/a,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:00:21,1641137555,5/22/2015 08:59:56,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],effective for,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:00:20,1641137558,5/22/2015 08:59:24,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[MANIFESTATION],[MANIFESTATION],"Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia",n/a,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:13:57,1641144347,5/22/2015 09:13:16,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],effective,-,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:41:01,1641157851,5/22/2015 09:38:32,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],effective,NA,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:51:02,1641162940,5/22/2015 09:50:49,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],effective,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 09:53:39,1641164297,5/22/2015 09:52:43,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[OTHER] [TREATS],"[TREATS]
[OTHER]","CAPSAICIN gabapentin, and oxycodone are effective for NEURALGIA HE<span id=""transmark""></span>RPES",n/a,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:00:51,1641168320,5/22/2015 10:00:37,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],effective,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:13:02,1641175342,5/22/2015 10:10:38,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],effective,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:18:30,1641178204,5/22/2015 10:16:51,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS],[TREATS],Tricyclic,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:19:28,1641178832,5/22/2015 10:19:17,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],effective,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:24:55,1641181870,5/22/2015 10:24:36,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],are effective for,n/a,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:25:40,1641182426,5/22/2015 10:24:15,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],Review: Keywords:,N/A,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919658,5/22/2015 10:26:18,1641182773,5/22/2015 10:25:07,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,just a rct,123,35,-1,138,44,TWrex-cause,804596-FS1,"Review: Tricyclic antidepressants, CAPSAICIN gabapentin, and oxycodone are effective for postherpetic neuralgia  Keywords: NEURALGIA HERPES zoster  ACP Journal Club.",NEURALGIA HERPES,CAPSAICIN
724919659,5/22/2015 08:36:51,1641126192,5/22/2015 08:36:19,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[CAUSES],[CAUSES],caused by,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 08:37:27,1641126428,5/22/2015 08:37:06,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],caused by,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 08:38:05,1641126769,5/22/2015 08:37:49,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[CAUSES],[CAUSES],caused by,n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 08:43:58,1641129362,5/22/2015 08:43:15,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:07:35,1641141236,5/22/2015 09:07:20,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[CAUSES],[CAUSES],caused,-,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:19:01,1641147093,5/22/2015 09:18:49,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[CAUSES],[CAUSES],caused,n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:24:26,1641149776,5/22/2015 09:24:12,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:38:17,1641156420,5/22/2015 09:37:45,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[CAUSES],[CAUSES],caused by the parasite,n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:42:23,1641158724,5/22/2015 09:41:52,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[CAUSES],[CAUSES],"UNCOMPLICATED MALARIA caused by PLASMODIUM FALCI<span id=""transmark""></span>PARUM",n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:45:50,1641160341,5/22/2015 09:45:36,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 09:57:20,1641166323,5/22/2015 09:57:06,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],caused,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 10:07:50,1641172440,5/22/2015 10:07:35,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],caused,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 10:09:08,1641173094,5/22/2015 10:08:36,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [PART_OF] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[IS_A]
[PART_OF]",is of caused by,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 10:10:44,1641174039,5/22/2015 10:09:33,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],caused by,N/A,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919659,5/22/2015 10:12:05,1641174719,5/22/2015 10:11:37,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[CAUSES],[CAUSES],caused by the,n/a,63,108,1,83,129,TWrex-cause,812377-FS1,BACKGROUND : Quinine is only FDA approved for the treatment of UNCOMPLICATED MALARIA caused by the parasite PLASMODIUM FALCIPARUM primarily in travelers returning from malaria endemic areas.,UNCOMPLICATED MALARIA,PLASMODIUM FALCIPARUM
724919660,5/22/2015 13:28:34,1641295829,5/22/2015 13:28:07,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CAUSES],[CAUSES],"etiologic agent,",N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 13:30:58,1641297176,5/22/2015 13:29:40,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],"etiologic agent,",N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 13:34:41,1641299321,5/22/2015 13:34:07,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[CAUSES],[CAUSES],"CMV, was not isolated",N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 13:38:26,1641301720,5/22/2015 13:37:16,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],was recognized,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 13:47:41,1641307167,5/22/2015 13:46:30,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[IS_A] [SYMPTOM],"[SYMPTOM]
[IS_A]",was recognized,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:14:06,1641315124,5/22/2015 14:12:19,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],CYTOMEGALOVIRUS Although CYTOMEGALIC INCLUSION DISEASE,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:15:06,1641315737,5/22/2015 14:14:28,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was recognized,n/a,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:32:28,1641326101,5/22/2015 14:32:16,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[PART_OF],[PART_OF],recognized,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:32:50,1641326246,5/22/2015 14:30:41,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[IS_A],[IS_A],"the etiologic agent,",n/a,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:33:08,1641326385,5/22/2015 14:32:38,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[OTHER],[OTHER],until,n/a,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:35:51,1641328096,5/22/2015 14:33:41,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[CAUSES],[CAUSES],Although was recognized as a clinical entity,n/a,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:38:31,1641329699,5/22/2015 14:37:25,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],recognized,none,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:38:32,1641329714,5/22/2015 14:36:49,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recognized,n/a,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:38:33,1641329734,5/22/2015 14:38:14,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919660,5/22/2015 14:50:46,1641336965,5/22/2015 14:50:07,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[IS_A],[IS_A],INCLUSION DISEASE,N/A,30,4,1,58,19,TWrex-cause,815007-FS1,"28  CYTOMEGALOVIRUS  Although CYTOMEGALIC INCLUSION DISEASE of infants was recognized as a clinical entity at the turn of the 20th century, the etiologic agent, CMV, was not isolated until the mid 1950s.",CYTOMEGALIC INCLUSION DISEASE,CYTOMEGALOVIRUS
724919661,5/22/2015 08:43:36,1641129184,5/22/2015 08:43:20,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],therapy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 08:44:02,1641129382,5/22/2015 08:43:44,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],therapy,n/a,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:03:03,1641138880,5/22/2015 09:02:12,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],therapy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:06:39,1641140711,5/22/2015 09:04:23,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]","Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy INTERVENTION After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",n/a,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:15:34,1641145222,5/22/2015 09:15:17,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],therapy,-,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:44:58,1641160004,5/22/2015 09:44:29,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],therapy,NA,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:52:07,1641163478,5/22/2015 09:51:51,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CONTRAINDICATES],[CONTRAINDICATES],expectancy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 09:58:00,1641166682,5/22/2015 09:56:45,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[OTHER] [TREATS],"[TREATS]
[OTHER]","other than VENOUS THROMBOEMBOLISM therapy with W<span id=""transmark""></span>ARFARIN",n/a,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:02:05,1641169004,5/22/2015 10:01:46,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[MANIFESTATION],[MANIFESTATION],expectancy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:14:02,1641175901,5/22/2015 10:13:48,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],therapy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:20:34,1641179404,5/22/2015 10:20:23,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[LOCATION],[LOCATION],"disorders,",N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:21:16,1641179704,5/22/2015 10:20:32,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",therapy with or therapy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:27:49,1641183732,5/22/2015 10:27:36,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],therapy,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:28:50,1641184256,5/22/2015 10:27:35,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],months of therapy with WARFARIN,N/A,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919661,5/22/2015 10:29:54,1641184876,5/22/2015 10:27:31,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],therapy with,n/a,73,188,-1,94,196,TWrex-cause,800158-FS1,"Exclusion criteria included anticoagulant therapy for reasons other than VENOUS THROMBOEMBOLISM major psychiatric disorders, life expectancy   INTERVENTION  After 3 months of therapy with WARFARIN (97% of patients) or acenocoumarol, 133 patients were allocated to discontinue (3 mo treatment group) and 133 patients to continue (1 y treatment group) oral anticoagulant therapy for 9 additional months.",VENOUS THROMBOEMBOLISM,WARFARIN
724919662,5/22/2015 10:43:20,1641193402,5/22/2015 10:43:00,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[IS_A] [TREATS],"[TREATS]
[IS_A]",a treatment,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 10:44:29,1641194093,5/22/2015 10:44:16,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],a treatment for,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 10:48:45,1641196652,5/22/2015 10:48:34,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],treatment,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 10:50:02,1641197412,5/22/2015 10:49:48,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],as a treatment for,N/a,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 10:51:02,1641198028,5/22/2015 10:50:52,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 10:53:52,1641199817,5/22/2015 10:53:22,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],as a treatment for,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 11:01:55,1641204581,5/22/2015 11:01:38,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],TACRINE as a treatment for ALZHEIMER'S DEMENTIA:,n/a,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 11:04:01,1641205916,5/22/2015 11:03:37,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A] [TREATS],"[TREATS]
[IS_A]",a treatment,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 11:31:42,1641222714,5/22/2015 11:30:36,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],ALZHEIMER'S DEMENTIA:,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 11:36:56,1641225767,5/22/2015 11:36:39,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A] [TREATS],"[TREATS]
[IS_A]",a treatment,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 12:51:11,1641271474,5/22/2015 12:50:48,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],TACRINE as treatment for ALZHEIMER'S DEMENTIA:,na,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 13:05:39,1641280371,5/22/2015 13:05:25,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],treatment for,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 13:08:34,1641282309,5/22/2015 13:08:23,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[LOCATION],[LOCATION],editor's,ffdf,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 13:10:50,1641283798,5/22/2015 13:10:18,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],treatment for,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919662,5/22/2015 13:11:51,1641284551,5/22/2015 13:10:45,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",as a treatment for,N/A,27,0,-1,46,7,TWrex-cause,800312-FS1,TACRINE as a treatment for ALZHEIMER'S DEMENTIA: editor's note.,ALZHEIMER'S DEMENTIA,TACRINE
724919663,5/22/2015 10:44:13,1641193952,5/22/2015 10:43:47,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with with,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 10:45:26,1641194696,5/22/2015 10:44:51,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Evaluation in,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 10:49:46,1641197249,5/22/2015 10:49:00,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[IS_A],[IS_A],in Severe,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 10:51:24,1641198278,5/22/2015 10:50:41,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],(RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]),N/a,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 11:03:07,1641205284,5/22/2015 11:02:31,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Cost effectiveness analysis from a patient perspective Markov model with benefit data controlled trial,n/a,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 11:05:31,1641206821,5/22/2015 11:04:48,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",a a with a with,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 11:32:31,1641223139,5/22/2015 11:31:59,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],(RECOMBINANT HUMAN ACTIVATED PROTEIN C,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 11:37:59,1641226339,5/22/2015 11:37:30,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",a with,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 12:53:20,1641272600,5/22/2015 12:52:37,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],(RECOMBINANT HUMAN ACTIVATED PROTEIN C in SEPSIS [PROWESS]),na,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:07:05,1641281358,5/22/2015 13:06:20,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],controlled trial,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:09:01,1641282589,5/22/2015 13:08:49,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[SYMPTOM],[SYMPTOM],benefit,fdff,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:12:24,1641284886,5/22/2015 13:11:25,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Evaluation in,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:15:12,1641286687,5/22/2015 13:13:41,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],effectiveness benefit,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:16:37,1641287735,5/22/2015 13:14:46,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[NONE]",Evaluation in,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919663,5/22/2015 13:17:14,1641288155,5/22/2015 13:16:22,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],Evaluation,N/A,299,230,-1,304,267,TWrex-cause,800557-FS1,"DESIGN  Cost effectiveness analysis from a patient perspective using a Markov model with benefit data from a {randomized (allocation concealed*), blinded (clinicians and patients),* placebo controlled trial with 28 day follow up (RECOMBINANT HUMAN ACTIVATED PROTEIN C Worldwide Evaluation in Severe SEPSIS [PROWESS]) +.",SEPSIS,RECOMBINANT HUMAN ACTIVATED PROTEIN C
724919664,5/22/2015 13:30:15,1641296766,5/22/2015 13:28:36,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],COMBINATION results,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 13:31:59,1641297741,5/22/2015 13:30:59,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",THERAPY for placebo controlled trial.,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 13:35:10,1641299637,5/22/2015 13:34:42,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",results from placebo controlled trial.,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 13:39:44,1641302506,5/22/2015 13:38:27,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],THERAPY for,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 13:48:22,1641307566,5/22/2015 13:47:44,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],THERAPY for,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:14:47,1641315528,5/22/2015 14:14:07,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS:,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:15:28,1641315915,5/22/2015 14:15:07,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],THERAPY,n/a,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:32:41,1641326172,5/22/2015 14:32:28,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[IS_A],[IS_A],results,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:33:18,1641326417,5/22/2015 14:32:51,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],THERAPY for,n/a,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:33:44,1641326668,5/22/2015 14:33:09,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],for,n/a,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:36:20,1641328349,5/22/2015 14:35:51,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS],[TREATS],THERAPY for,n/a,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:38:56,1641330058,5/22/2015 14:38:34,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],THERAPY,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:39:03,1641330120,5/22/2015 14:38:32,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[PREVENTS],[PREVENTS],for,none,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:39:08,1641330142,5/22/2015 14:38:33,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results,n/a,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919664,5/22/2015 14:51:02,1641337131,5/22/2015 14:50:48,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],for,N/A,123,71,-1,149,118,TWrex-cause,800713-FS1,"1]  Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY for POSTMENOPAUSAL OSTEOPOROSIS: results from a 6 month double blind placebo controlled trial.",POSTMENOPAUSAL OSTEOPOROSIS,COMBINATION TERIPARATIDE AND RALOXIFENE THERAPY
724919665,5/22/2015 10:37:41,1641189800,5/22/2015 10:37:19,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:40:50,1641191648,5/22/2015 10:38:35,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",is of with with,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:42:56,1641193118,5/22/2015 10:42:42,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],the treatment of,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:47:35,1641196042,5/22/2015 10:47:24,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:47:41,1641196067,5/22/2015 10:47:22,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],is approved for the treatment of,N/a,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:49:28,1641197024,5/22/2015 10:49:00,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],the treatment,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:49:53,1641197323,5/22/2015 10:49:44,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 10:59:12,1641202869,5/22/2015 10:58:41,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS,n/a,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 11:00:44,1641203830,5/22/2015 11:00:08,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A] [TREATS] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",is treatment of with with with,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 11:26:35,1641219293,5/22/2015 11:26:06,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",is of with with with,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 11:27:09,1641219667,5/22/2015 11:26:47,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],ANOREXIA,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 12:45:48,1641268374,5/22/2015 12:44:10,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],DRONABINOL for the treatment of ANOREXIA,na,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 12:46:24,1641268662,5/22/2015 12:46:06,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treatment,na,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 12:51:36,1641271657,5/22/2015 12:50:48,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],approved for the treatment,n/a,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919665,5/22/2015 13:02:18,1641278149,5/22/2015 13:01:41,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],approved for the treatment of,N/A,62,18,-1,69,28,TWrex-cause,803827-FS1,"59   In addition, DRONABINOL is approved for the treatment of ANOREXIA associated with weight loss in patients with AIDS (starting with 2.5 mg twice daily, before lunch and supper, and titrating to effect and tolerability.",ANOREXIA,DRONABINOL
724919666,5/22/2015 08:44:15,1641129442,5/22/2015 08:43:53,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[SIDE_EFFECT],[SIDE_EFFECT],can result,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 08:44:48,1641129732,5/22/2015 08:44:23,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[CAUSES],[CAUSES],can result in,n/a,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 09:03:52,1641139283,5/22/2015 09:03:23,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],can result in,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 09:08:36,1641141700,5/22/2015 09:07:13,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[CAUSES] [CONTRAINDICATES] [TREATS],"[TREATS]
[CAUSES]
[CONTRAINDICATES]","LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",n/a,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 09:16:19,1641145541,5/22/2015 09:15:51,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SIDE_EFFECT],[SIDE_EFFECT],result,-,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 09:48:04,1641161463,5/22/2015 09:46:07,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SIDE_EFFECT],[SIDE_EFFECT],result,NA,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 09:52:38,1641163804,5/22/2015 09:52:24,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],result,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:00:44,1641168245,5/22/2015 09:58:54,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[CAUSES],[CAUSES],"LONG TERM LEAD EXPOSURE result in SATURNINE GO<span id=""transmark""></span>UT",n/a,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:02:42,1641169345,5/22/2015 10:02:28,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],reduced,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:14:31,1641176220,5/22/2015 10:14:18,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],reduced,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:21:03,1641179582,5/22/2015 10:20:51,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],reduced,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:22:28,1641180474,5/22/2015 10:21:52,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:28:32,1641184051,5/22/2015 10:28:08,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],reduced,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:28:48,1641184222,5/22/2015 10:28:23,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],can result in,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919666,5/22/2015 10:29:37,1641184721,5/22/2015 10:28:52,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],can result in chronic,N/A,128,10,1,141,33,TWrex-cause,811170-FS1,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
724919667,5/22/2015 08:45:03,1641129872,5/22/2015 08:44:16,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[DIAGNOSE_BY_TEST_OR_DRUG] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]",reduced risk for,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 08:45:05,1641129874,5/22/2015 08:44:49,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[PREVENTS],[PREVENTS],reduced risk,n/a,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 09:04:28,1641139708,5/22/2015 09:03:53,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[PREVENTS],[PREVENTS],reduced risk,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 09:09:43,1641142229,5/22/2015 09:08:37,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","CONCLUSION In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",n/a,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 09:16:42,1641145774,5/22/2015 09:16:20,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],reduced,-,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 09:49:50,1641162304,5/22/2015 09:48:05,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SIDE_EFFECT],[SIDE_EFFECT],reduced risk,NA,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 09:52:51,1641163928,5/22/2015 09:52:40,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SYMPTOM],[SYMPTOM],systemic,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:02:16,1641169095,5/22/2015 10:00:46,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS] [OTHER],"[TREATS]
[OTHER]","STROKE WA<span id=""transmark""></span>RFARIN",n/a,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:02:57,1641169457,5/22/2015 10:02:45,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],systemic,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:14:44,1641176336,5/22/2015 10:14:32,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],similar,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:21:21,1641179782,5/22/2015 10:21:06,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],reduced,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:23:08,1641180911,5/22/2015 10:22:32,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[PART_OF]",with or of,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:29:03,1641184425,5/22/2015 10:28:33,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[SYMPTOM],[SYMPTOM],systemic,Choose the valid RELATION(s) between the TERMS in the SENTENCE,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:29:51,1641184857,5/22/2015 10:28:51,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[PREVENTS],[PREVENTS],reduced risk for STROKE more than,N/A,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919667,5/22/2015 10:31:50,1641186044,5/22/2015 10:29:33,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,none,99,137,-1,104,145,TWrex-cause,804882-FS1,"CONCLUSION  In patients with atrial fibrillation, dabigatran, 150 mg twice daily, reduced risk for STROKE or systemic embolism more than WARFARIN and had similar rates of major hemorrhage.",STROKE,WARFARIN
724919668,5/22/2015 10:24:58,1641181903,5/22/2015 10:24:42,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[SYMPTOM],[SYMPTOM],rebound,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:35:02,1641188076,5/22/2015 10:34:41,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],become,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:35:22,1641188241,5/22/2015 10:34:54,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[PART_OF]",with by of of drugs,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:37:12,1641189516,5/22/2015 10:36:39,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",incapacitated by the headache,n/a,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:39:36,1641190960,5/22/2015 10:38:30,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",MIGRAINE who develop HEADACHE,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:40:53,1641191706,5/22/2015 10:40:00,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],become severely incapacitated by the headache,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:43:16,1641193359,5/22/2015 10:42:39,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[PART_OF],[PART_OF],who usually become severely incapacitated by the headache,N/a,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:45:22,1641194640,5/22/2015 10:45:10,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[SYMPTOM],[SYMPTOM],headache,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:47:28,1641195988,5/22/2015 10:47:05,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:53:57,1641199836,5/22/2015 10:53:18,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study excluded the 25% to 35% patients with MIGRAINE usually become severely incapacitated by the headache,n/a,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 10:54:57,1641200462,5/22/2015 10:54:16,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with of is of drugs,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 11:16:05,1641213278,5/22/2015 11:15:19,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[SYMPTOM],[SYMPTOM],attributed to,Indicates that drug use causes this.,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 11:22:10,1641216779,5/22/2015 11:21:51,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],HEADACHE,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 11:22:20,1641216864,5/22/2015 11:21:48,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with by of is of drugs,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919668,5/22/2015 12:15:52,1641248750,5/22/2015 12:15:04,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[IS_A],[IS_A],MIGRAINE who develop HEADACHE,N/A,179,52,1,186,60,TWrex-cause,813474-FS1,"This study excluded the 25% to 35% of patients with MIGRAINE who usually become severely incapacitated by the headache and the indeterminate number of persons who develop rebound HEADACHE that is often attributed to the overenthusiastic use of nonprescription drugs that contain caffeine (1, 2.",HEADACHE,MIGRAINE
724919669,5/22/2015 13:00:15,1641276874,5/22/2015 12:59:41,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],PHOTOAGING result of ULTRAVIOLET RAYS,na,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:10:43,1641283718,5/22/2015 13:10:20,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CAUSES],[CAUSES],as a result of exposure,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:21:22,1641290895,5/22/2015 13:20:35,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],result of,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:23:21,1641292370,5/22/2015 13:22:58,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CAUSES],[CAUSES],as a result of,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:26:59,1641294837,5/22/2015 13:26:45,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[CAUSES],[CAUSES],as a result of exposure,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:27:23,1641295086,5/22/2015 13:26:07,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[MANIFESTATION],[MANIFESTATION],as a result of,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:33:47,1641298870,5/22/2015 13:31:33,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [NONE],"[CAUSES]
[NONE]",as a result of exposure,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:39:12,1641302264,5/22/2015 13:38:34,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SIDE_EFFECT],[SIDE_EFFECT],as a result of,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 13:45:24,1641305747,5/22/2015 13:44:57,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[CAUSES],[CAUSES],PHOTOAGING result exposure to ULTRAVIOLET RAYS,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:10:40,1641312642,5/22/2015 14:10:16,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[CAUSES],[CAUSES],as a result of,n/a,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:21:02,1641319076,5/22/2015 14:20:30,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[CAUSES],[CAUSES],as a result of,n/a,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:22:46,1641320276,5/22/2015 14:21:57,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[SIDE_EFFECT],[SIDE_EFFECT],as a result of exposure,n/a,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:27:19,1641323115,5/22/2015 14:26:55,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[CAUSES],[CAUSES],result of,n/a,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:30:10,1641324630,5/22/2015 14:29:59,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[CAUSES],[CAUSES],result,N/A,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919669,5/22/2015 14:32:47,1641326225,5/22/2015 14:32:26,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],result,none,0,53,1,9,69,TWrex-cause,811572-FS1,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
724919670,5/22/2015 13:07:48,1641281702,5/22/2015 13:06:52,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],malformations increased with use of VALPROIC ACID during PREGNANCY,na,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:12:49,1641285262,5/22/2015 13:12:25,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CONTRAINDICATES],[CONTRAINDICATES],Risk substantially increased,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:24:23,1641293002,5/22/2015 13:23:44,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CONTRAINDICATES] [CAUSES],"[CAUSES]
[CONTRAINDICATES]",malformations is substantially increased,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:24:38,1641293179,5/22/2015 13:24:18,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CONTRAINDICATES],[CONTRAINDICATES],Risk substantially increased,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:27:50,1641295335,5/22/2015 13:27:29,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],with use of,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:30:41,1641297023,5/22/2015 13:29:34,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CONTRAINDICATES],[CONTRAINDICATES],Risk substantially increased with,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:41:18,1641303437,5/22/2015 13:38:58,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [SIDE_EFFECT] [NONE],"[CAUSES]
[SIDE_EFFECT]
[NONE]",use of,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:41:36,1641303599,5/22/2015 13:40:44,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SIDE_EFFECT],[SIDE_EFFECT],use of,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 13:49:31,1641308221,5/22/2015 13:47:40,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],Risk with use of VALPROIC ACID during PREGNANCY,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:12:21,1641313954,5/22/2015 14:11:50,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared with,n/a,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:24:16,1641321122,5/22/2015 14:23:28,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SIDE_EFFECT],[SIDE_EFFECT],increased with use of,n/a,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:25:37,1641321930,5/22/2015 14:24:24,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],compared with other antiepileptic drugs,n/a,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:29:38,1641324341,5/22/2015 14:29:06,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[CAUSES],[CAUSES],is substantially increased,n/a,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:30:58,1641325160,5/22/2015 14:30:42,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[MANIFESTATION],[MANIFESTATION],congenital malformations,N/A,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919670,5/22/2015 14:34:29,1641327170,5/22/2015 14:33:54,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CONTRAINDICATES],[CONTRAINDICATES],Risk substantially increased,none,223,162,-1,231,175,TWrex-cause,803157-FS1,"182 ,   183 ,   184 ,   185 ,   188 ,   189 ,   190 ,   191 ,   192 ,   194 ,   b   Risk of major congenital malformations is substantially increased with use of VALPROIC ACID compared with other antiepileptic drugs during PREGNANCY",PREGNANCY,VALPROIC ACID
724919671,5/22/2015 08:36:03,1641125742,5/22/2015 08:35:41,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[MANIFESTATION],[MANIFESTATION],results from,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 08:36:35,1641126044,5/22/2015 08:35:57,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],results from reactivation,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 08:37:35,1641126518,5/22/2015 08:37:22,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[CAUSES],[CAUSES],results from,n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 08:42:34,1641128776,5/22/2015 08:41:56,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[CAUSES],[CAUSES],Herpes Zoster HERPES ZOSTER results from the reactivation of VZV INFECTION,n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:07:02,1641140895,5/22/2015 09:06:28,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SIDE_EFFECT],[SIDE_EFFECT],results,-,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:18:34,1641146848,5/22/2015 09:18:20,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[CAUSES],[CAUSES],results from,n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:21:58,1641148509,5/22/2015 09:20:46,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SIDE_EFFECT],[SIDE_EFFECT],results,NA,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:37:23,1641156050,5/22/2015 09:34:41,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",results,n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:40:59,1641157858,5/22/2015 09:40:19,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[CAUSES],[CAUSES],"HERPES ZOSTER results from VZV INFE<span id=""transmark""></span>CTION",n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:45:19,1641160165,5/22/2015 09:45:05,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],results,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 09:56:49,1641165993,5/22/2015 09:56:34,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],results,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 10:07:21,1641172105,5/22/2015 10:07:09,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],results,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 10:08:02,1641172545,5/22/2015 10:07:38,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 10:08:42,1641172850,5/22/2015 10:07:21,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],results from,N/A,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919671,5/22/2015 10:11:12,1641174239,5/22/2015 10:10:36,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[CAUSES],[CAUSES],results from,n/a,62,15,1,74,28,TWrex-cause,810761-FS1,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
724919672,5/22/2015 13:39:18,1641302306,5/22/2015 13:38:59,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[SYMPTOM] [MANIFESTATION] [PART_OF],"[SYMPTOM]
[MANIFESTATION]
[PART_OF]",is infection with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 13:39:27,1641302371,5/22/2015 13:38:41,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CAUSES],[CAUSES],infection with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 13:51:13,1641309165,5/22/2015 13:50:08,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],is infection with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:13:10,1641314514,5/22/2015 14:10:37,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[IS_A],[IS_A],is,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:19:27,1641318259,5/22/2015 14:19:12,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[CAUSES],[CAUSES],is infection with,n,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:37:59,1641329334,5/22/2015 14:37:34,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[PART_OF],[PART_OF],with,n/a,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:41:36,1641331527,5/22/2015 14:41:19,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],is with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:41:40,1641331564,5/22/2015 14:40:47,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[CAUSES],[CAUSES],TOXOPLASMOSIS TOXOPLASMOSIS is infection TOXOPLASMA GONDII.,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:43:41,1641332936,5/22/2015 14:43:11,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[SIDE_EFFECT],[SIDE_EFFECT],infection,n/a,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:44:33,1641333341,5/22/2015 14:43:50,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",is infection with,n/a,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:44:46,1641333461,5/22/2015 14:44:11,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[CAUSES],[CAUSES],is infection with,n/a,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:45:54,1641334059,5/22/2015 14:45:31,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CAUSES],[CAUSES],is infection,none,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:55:43,1641340181,5/22/2015 14:55:19,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[IS_A],[IS_A],is infection with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:58:08,1641341857,5/22/2015 14:57:35,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is infection with,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919672,5/22/2015 14:58:39,1641342203,5/22/2015 14:58:26,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[SYMPTOM],[SYMPTOM],infection,N/A,0,48,1,12,65,TWrex-cause,812422-FS1,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
724919673,5/22/2015 14:14:08,1641315150,5/22/2015 14:13:11,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SYMPTOM],[SYMPTOM],occurs,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:19:46,1641318458,5/22/2015 14:19:28,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Consider the possibility of,n,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:38:33,1641329736,5/22/2015 14:38:01,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[CAUSES],[CAUSES],using,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:41:56,1641331700,5/22/2015 14:41:37,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[CAUSES],[CAUSES],using,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:43:36,1641332840,5/22/2015 14:41:41,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],possibility of ectopic pregnancy if PREGNANCY occurs using MEDROXYPROGESTERONE,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:43:59,1641333051,5/22/2015 14:43:42,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],using,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:45:39,1641333918,5/22/2015 14:44:34,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SIDE_EFFECT],[SIDE_EFFECT],occurs in women using,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:45:58,1641334114,5/22/2015 14:44:47,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[CAUSES],[CAUSES],severe abdominal pain,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:46:35,1641334518,5/22/2015 14:45:56,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],occurs using,none,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:56:23,1641340622,5/22/2015 14:55:45,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[PREVENTS],[PREVENTS],CONTRACEPTION.,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:59:18,1641342639,5/22/2015 14:58:11,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[MANIFESTATION],[MANIFESTATION],occurs in,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 14:59:28,1641342754,5/22/2015 14:59:03,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[SYMPTOM],[SYMPTOM],possibility of,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 15:05:49,1641346474,5/22/2015 15:03:32,false,clixsense,1.0,30544555,USA,TX,Longview,208.180.9.42,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",pain occurs women using,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 15:37:37,1641366102,5/22/2015 15:36:42,false,neodev,1.0,31294288,USA,IL,Chicago,67.212.188.11,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]",occurs in women using,N/A,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919673,5/22/2015 15:40:37,1641368068,5/22/2015 15:40:06,false,elite,1.0,31883685,GBR,H2,Accrington,80.47.186.28,[SIDE_EFFECT],[SIDE_EFFECT],possibility of,n/a,68,125,-1,76,158,TWrex-cause,803315-FS1,Ectopic Pregnancy  Consider the possibility of ectopic pregnancy if PREGNANCY or severe abdominal pain occurs in women using MEDROXYPROGESTERONE CONTRACEPTION.,PREGNANCY,MEDROXYPROGESTERONE CONTRACEPTION
724919674,5/22/2015 10:44:43,1641194273,5/22/2015 10:44:17,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]",or without causing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 10:46:38,1641195473,5/22/2015 10:45:27,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],may blunt and decreasing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 10:50:02,1641197399,5/22/2015 10:49:48,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 10:52:10,1641198786,5/22/2015 10:51:26,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],"may blunt the medullary response to CO 2 retention or O 2 decline, reducing",N/a,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 11:03:40,1641205646,5/22/2015 11:03:08,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES] [TREATS],"[TREATS]
[CAUSES]","Low dose MORPHINE may blunt the medullary response to CO retention or O 2 decline, reducing DYSPNEA and decreasing anxiety",n/a,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 11:06:06,1641207128,5/22/2015 11:05:34,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",without causing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 11:33:15,1641223563,5/22/2015 11:32:32,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],anxiety,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 11:38:26,1641226619,5/22/2015 11:38:01,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]",or without causing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 12:53:48,1641272972,5/22/2015 12:53:21,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],MORPHINE reducing DYSPNEA,na,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:07:28,1641281572,5/22/2015 13:07:07,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:09:15,1641282733,5/22/2015 13:09:03,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DYSPNEA,fdf,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:12:57,1641285332,5/22/2015 13:12:27,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[PREVENTS],[PREVENTS],reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:16:20,1641287492,5/22/2015 13:15:13,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[PREVENTS],[PREVENTS],reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:18:00,1641288697,5/22/2015 13:17:16,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919674,5/22/2015 13:18:40,1641289132,5/22/2015 13:16:39,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",reducing,N/A,96,9,-1,102,17,TWrex-cause,800687-FS1,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
724919675,5/22/2015 11:40:12,1641227616,5/22/2015 11:39:10,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],CEREBRAL MALARIA,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 12:58:22,1641275735,5/22/2015 12:56:46,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM,na,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:09:24,1641282798,5/22/2015 13:09:06,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:18:29,1641289001,5/22/2015 13:16:36,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:22:02,1641291255,5/22/2015 13:21:09,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[MANIFESTATION],[MANIFESTATION],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:23:13,1641292273,5/22/2015 13:21:56,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:26:17,1641294321,5/22/2015 13:26:02,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:28:37,1641295844,5/22/2015 13:26:34,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [NONE],"[CAUSES]
[NONE]","Smear negative, due to",N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:37:27,1641301041,5/22/2015 13:36:07,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 13:43:57,1641304886,5/22/2015 13:42:53,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[CAUSES],[CAUSES],CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 14:09:25,1641311249,5/22/2015 14:09:07,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[CAUSES],[CAUSES],due to,n/a,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 14:19:22,1641318214,5/22/2015 14:18:51,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[CAUSES],[CAUSES],due to,n/a,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 14:21:07,1641319149,5/22/2015 14:18:41,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[SIDE_EFFECT],[SIDE_EFFECT],due to MEFLOQUINE RESISTANT,n/a,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 14:25:48,1641322020,5/22/2015 14:25:29,false,instagc,1,25990856,USA,NV,Las Vegas,98.160.220.169,[CAUSES],[CAUSES],due to,n/a,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919675,5/22/2015 14:29:29,1641324251,5/22/2015 14:29:06,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[CAUSES],[CAUSES],due to,N/A,15,39,1,30,81,TWrex-cause,811457-FS1,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
724919676,5/22/2015 10:35:57,1641188563,5/22/2015 10:35:42,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[IS_A],[IS_A],"(e.g.,",N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:36:27,1641188894,5/22/2015 10:36:09,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or,N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:38:46,1641190481,5/22/2015 10:38:03,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[IS_A],[IS_A],"(e.g.,",n/a,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:40:31,1641191528,5/22/2015 10:40:13,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[IS_A],[IS_A],"(e.g.,",N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:43:34,1641193509,5/22/2015 10:42:31,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],"PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]),",N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:44:58,1641194396,5/22/2015 10:44:34,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[IS_A],[IS_A],"PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]),",N/a,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:46:08,1641195226,5/22/2015 10:45:54,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[IS_A],[IS_A],"(e.g.,",N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:48:26,1641196487,5/22/2015 10:48:09,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[IS_A],[IS_A],"(e.g.,",n/a,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:56:06,1641201076,5/22/2015 10:55:09,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Avoid use for malignant PREMALIGNANT SKIN CONDITIONS,n/a,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 10:57:11,1641201805,5/22/2015 10:56:39,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or,N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 11:23:25,1641217522,5/22/2015 11:23:07,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or,N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 11:23:32,1641217589,5/22/2015 11:23:12,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[LOCATION],[LOCATION],dermatitis.,N/A,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 12:23:15,1641253304,5/22/2015 12:23:06,false,neodev,1.0,31789301,NLD,"","",146.185.183.119,[NONE],[NONE],no,no,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 12:34:51,1641261695,5/22/2015 12:33:06,false,elite,1.0,31526431,USA,CA,Elk Grove,67.166.135.122,[DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[NONE]",good,good,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919676,5/22/2015 12:37:11,1641263257,5/22/2015 12:35:50,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[IS_A],[IS_A],"PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]),",na,27,63,-1,54,88,TWrex-cause,802748-FS1,"Avoid use for malignant or PREMALIGNANT SKIN CONDITIONS (e.g., CUTANEOUS T CELL LYMPHOMA [CTCL]), which may appear clinically similar to dermatitis.",PREMALIGNANT SKIN CONDITIONS,CUTANEOUS T CELL LYMPHOMA
724919677,5/22/2015 13:31:51,1641297670,5/22/2015 13:31:10,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],efficacy in relieving,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 13:34:32,1641299264,5/22/2015 13:33:08,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],in relieving,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 13:35:48,1641300029,5/22/2015 13:35:34,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],overall efficacy in relieving,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 13:42:03,1641303949,5/22/2015 13:40:52,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],efficacy,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 13:50:21,1641308679,5/22/2015 13:49:15,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SYMPTOM],[SYMPTOM],have efficacy related symptoms,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:16:11,1641316273,5/22/2015 14:15:43,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],Once daily,n/a,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:34:24,1641327105,5/22/2015 14:34:06,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[SYMPTOM],[SYMPTOM],related symptoms,n/a,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:34:47,1641327417,5/22/2015 14:33:40,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[NONE],[NONE],N/A,"there is no relation, they were asking a question",359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:36:00,1641328199,5/22/2015 14:34:22,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],in relieving symptoms,n/a,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:38:45,1641329928,5/22/2015 14:37:25,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]","have equivalent overall efficacy there any association between myocardial infarction,",n/a,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:39:21,1641330298,5/22/2015 14:39:09,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[SYMPTOM],[SYMPTOM],symptoms:,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:39:42,1641330479,5/22/2015 14:39:26,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[SYMPTOM],[SYMPTOM],symptoms:,n/a,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:40:17,1641330851,5/22/2015 14:39:50,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],relieving,none,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:51:33,1641337419,5/22/2015 14:51:03,false,clixsense,1,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],have equivalent overall efficacy,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919677,5/22/2015 14:54:40,1641339295,5/22/2015 14:53:51,false,bitcoinget,1,21743413,USA,WA,Lynnwood,67.183.5.219,[TREATS],[TREATS],have equivalent overall efficacy in relieving,N/A,359,192,-1,391,204,TWrex-cause,804373-FS1,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
724919678,5/22/2015 08:38:11,1641126811,5/22/2015 08:37:55,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[SYMPTOM],[SYMPTOM],generalized,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 08:39:25,1641127382,5/22/2015 08:39:03,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 08:40:32,1641127943,5/22/2015 08:39:46,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[MANIFESTATION],[MANIFESTATION],with,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 08:47:34,1641131188,5/22/2015 08:46:45,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[SYMPTOM],[SYMPTOM],Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:09:08,1641141918,5/22/2015 09:08:36,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SIDE_EFFECT],[SIDE_EFFECT],unexplained generalized,-,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:19:52,1641147521,5/22/2015 09:19:39,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[PART_OF],[PART_OF],in patients with,n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:28:30,1641152037,5/22/2015 09:26:51,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SYMPTOM],[SYMPTOM],SEIZURES,NA,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:42:32,1641158818,5/22/2015 09:41:40,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[SYMPTOM],[SYMPTOM],patients with,n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:45:56,1641160405,5/22/2015 09:44:51,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]","SEIZURES in patients with preE<span id=""transmark""></span>CLAMPSIA.",n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:46:59,1641160946,5/22/2015 09:46:37,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SYMPTOM],[SYMPTOM],patients with,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 09:58:20,1641166897,5/22/2015 09:58:06,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],with,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 10:08:44,1641172870,5/22/2015 10:08:33,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],generalized,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 10:12:02,1641174696,5/22/2015 10:11:30,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",is with,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 10:14:30,1641176213,5/22/2015 10:13:59,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],in patients with,N/A,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919678,5/22/2015 10:14:41,1641176329,5/22/2015 10:13:59,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[SYMPTOM],[SYMPTOM],unexplained generalized,n/a,37,66,1,44,75,TWrex-cause,814695-FS1,Eclampsia is unexplained generalized SEIZURES in patients with preECLAMPSIA.,SEIZURES,ECLAMPSIA
724919679,5/22/2015 08:45:46,1641130276,5/22/2015 08:45:31,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],revealed,n/a,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 08:45:59,1641130437,5/22/2015 08:45:39,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Investigations of the prevalence,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 09:06:01,1641140464,5/22/2015 09:05:12,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence of,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 09:11:53,1641143272,5/22/2015 09:10:46,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[OTHER],[OTHER],"Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",n/a,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 09:17:27,1641146131,5/22/2015 09:17:08,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[MANIFESTATION],[MANIFESTATION],revealed,-,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 09:53:08,1641164124,5/22/2015 09:51:23,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[MANIFESTATION],[MANIFESTATION],prevalence,NA,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 09:53:52,1641164450,5/22/2015 09:53:39,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SIDE_EFFECT],[SIDE_EFFECT],revealed,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:03:44,1641169922,5/22/2015 10:03:31,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],revealed,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:05:40,1641171176,5/22/2015 10:04:24,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NORMAL SCABIES revealed live MITES,n/a,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:15:27,1641176752,5/22/2015 10:15:15,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Investigations,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:22:05,1641180296,5/22/2015 10:21:52,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[SYMPTOM],[SYMPTOM],revealed,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:25:00,1641181974,5/22/2015 10:24:23,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:30:38,1641185384,5/22/2015 10:30:20,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[LOCATION],[LOCATION],revealed,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:31:21,1641185766,5/22/2015 10:30:12,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence of mites in the personal environment,n/a,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919679,5/22/2015 10:31:42,1641185964,5/22/2015 10:30:31,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],Investigations revealed,N/A,87,116,1,100,121,TWrex-cause,811101-FS1,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
724919680,5/22/2015 10:24:26,1641181702,5/22/2015 10:24:13,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[SYMPTOM],[SYMPTOM],symptoms,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:34:22,1641187539,5/22/2015 10:34:06,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[SYMPTOM],[SYMPTOM],symptoms,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:34:27,1641187637,5/22/2015 10:33:48,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[SYMPTOM] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]","symptoms (with or without of symptoms, with",N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:36:17,1641188771,5/22/2015 10:35:57,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[SYMPTOM],[SYMPTOM],symptoms can include,n/a,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:36:50,1641189233,5/22/2015 10:36:31,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[SYMPTOM],[SYMPTOM],Presenting symptoms can include,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:39:04,1641190639,5/22/2015 10:38:17,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],Presenting symptoms,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:42:10,1641192617,5/22/2015 10:41:49,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[SYMPTOM],[SYMPTOM],Presenting symptoms can include,N/a,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:43:33,1641193513,5/22/2015 10:43:21,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[SYMPTOM],[SYMPTOM],symptoms,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:46:52,1641195597,5/22/2015 10:46:41,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],symptoms,n/a,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:52:49,1641199180,5/22/2015 10:52:25,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],"CROHN'S DISEASE Presenting symptoms can include DIARRHEA fever, weight loss, fatigue and abdominal pain",n/a,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 10:53:34,1641199680,5/22/2015 10:52:47,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]","symptoms (with or without of symptoms,",N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 11:14:41,1641212451,5/22/2015 11:14:03,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[SYMPTOM],[SYMPTOM],symptoms can include,Directly states some symptoms.,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 11:21:01,1641215985,5/22/2015 11:20:42,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],"DIARRHEA fever, weight loss, fatigue abdominal pain",N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 11:21:17,1641216169,5/22/2015 11:20:46,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]","symptoms (with or without of symptoms, with",N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919680,5/22/2015 11:57:43,1641237678,5/22/2015 11:57:11,false,neodev,1,11001780,AUS,07,Elwood,14.201.215.31,[SYMPTOM],[SYMPTOM],symptoms,N/A,49,0,1,56,15,TWrex-cause,812674-FS1,"CROHN'S DISEASE  Presenting symptoms can include DIARRHEA (with or without blood), fever, weight loss, fatigue and abdominal pain  History, chronicity of symptoms, and colonoscopic exam with biopsy may differentiate the disorders.",DIARRHEA,CROHN'S DISEASE
724919681,5/22/2015 08:37:54,1641126703,5/22/2015 08:37:41,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 08:39:03,1641127145,5/22/2015 08:38:38,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 08:39:44,1641127557,5/22/2015 08:38:36,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[PREVENTS],[PREVENTS],"ESTROGEN containing contraceptives,",N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 08:46:44,1641130836,5/22/2015 08:45:38,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[MANIFESTATION],[MANIFESTATION],"WOMEN'S HEALTH VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:08:36,1641141701,5/22/2015 09:08:09,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[PART_OF],[PART_OF],containing,-,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:19:38,1641147418,5/22/2015 09:19:25,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[CAUSES],[CAUSES],associated,n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:26:50,1641150995,5/22/2015 09:25:48,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],therapy.,NA,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:41:39,1641158186,5/22/2015 09:40:45,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:44:50,1641159922,5/22/2015 09:43:52,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]","problem associated with ESTROGEN PREGNANCY a<span id=""transmark""></span>nd",n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:46:36,1641160739,5/22/2015 09:46:23,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 09:58:04,1641166728,5/22/2015 09:57:51,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 10:08:31,1641172724,5/22/2015 10:08:17,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 10:11:27,1641174431,5/22/2015 10:10:39,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",is a is with,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 10:13:56,1641175792,5/22/2015 10:12:57,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],associated with,N/A,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919681,5/22/2015 10:13:57,1641175806,5/22/2015 10:13:26,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,119,78,-1,127,86,TWrex-cause,803204-FS1,"WOMEN'S HEALTH  VTE is a women's health problem because it is associated with ESTROGEN containing oral contraceptives, PREGNANCY and postmenopausal hormone replacement therapy.",PREGNANCY,ESTROGEN
724919682,5/22/2015 08:45:30,1641130092,5/22/2015 08:45:19,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],Treatment,n/a,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 08:45:38,1641130182,5/22/2015 08:45:22,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[CAUSES],[CAUSES],caused by,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 09:05:11,1641140101,5/22/2015 09:04:52,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[CAUSES],[CAUSES],caused by,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 09:10:45,1641142825,5/22/2015 09:10:11,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",CAMPYLOBACTER INFECTIONS Treatment of infections caused by CAMPYLOBACTER,n/a,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 09:17:07,1641145971,5/22/2015 09:16:56,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],Treatment,-,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 09:51:22,1641163075,5/22/2015 09:51:04,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[CAUSES],[CAUSES],caused,NA,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 09:53:37,1641164294,5/22/2015 09:53:07,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[CAUSES],[CAUSES],caused,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:03:29,1641169750,5/22/2015 10:03:15,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",Treatment caused,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:04:21,1641170213,5/22/2015 10:03:06,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"CAMPYLOBACTER INFECTIONS Treatment of infections caused b<span id=""transmark""></span>y CAMPYLOBACTER",n/a,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:15:14,1641176642,5/22/2015 10:14:59,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[CAUSES],[CAUSES],caused,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:21:50,1641180078,5/22/2015 10:21:37,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],Treatment,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:24:20,1641181663,5/22/2015 10:23:45,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",of caused by,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:30:11,1641185079,5/22/2015 10:29:55,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[CAUSES],[CAUSES],caused by,n/a,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:30:19,1641185201,5/22/2015 10:29:31,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],caused,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919682,5/22/2015 10:30:31,1641185276,5/22/2015 10:30:07,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF] [TREATS] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",of caused by,N/A,3,3,1,26,16,TWrex-cause,810772-FS1,i  CAMPYLOBACTER INFECTIONS  Treatment of infections caused by  CAMPYLOBACTER,CAMPYLOBACTER INFECTIONS,CAMPYLOBACTER
724919683,5/22/2015 12:59:40,1641276665,5/22/2015 12:59:24,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"SEIZURES associated with EPILEPSY glomerulonephritis,",na,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:10:20,1641283474,5/22/2015 13:09:52,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[MANIFESTATION],[MANIFESTATION],associated,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:20:34,1641290398,5/22/2015 13:19:08,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:22:57,1641292113,5/22/2015 13:22:24,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:26:06,1641294203,5/22/2015 13:24:59,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:26:44,1641294633,5/22/2015 13:26:32,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:31:31,1641297421,5/22/2015 13:30:44,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[ASSOCIATED_WITH] [NONE],"[ASSOCIATED_WITH]
[NONE]",associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:38:32,1641301768,5/22/2015 13:38:04,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 13:44:55,1641305479,5/22/2015 13:44:30,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with EPILEPSY,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:10:15,1641312061,5/22/2015 14:09:52,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[MANIFESTATION],[MANIFESTATION],associated with,n/a,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:20:29,1641318776,5/22/2015 14:20:02,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:21:56,1641319574,5/22/2015 14:21:29,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:26:54,1641322832,5/22/2015 14:26:09,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:29:59,1641324540,5/22/2015 14:29:46,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919683,5/22/2015 14:32:26,1641326043,5/22/2015 14:31:57,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[SYMPTOM],[SYMPTOM],associated,none,47,72,1,54,80,TWrex-cause,813403-FS1,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
724919684,5/22/2015 14:16:14,1641316286,5/22/2015 14:14:09,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[SYMPTOM],[SYMPTOM],adjusted therapy,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:20:10,1641318600,5/22/2015 14:19:47,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",anticoagulation therapy,n,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:38:58,1641330071,5/22/2015 14:38:34,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],therapy,n/a,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:42:30,1641332065,5/22/2015 14:41:57,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:44:57,1641333552,5/22/2015 14:44:01,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],dose,n/a,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:46:02,1641334116,5/22/2015 14:43:37,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],adjusted dose warfarin Event rate SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:47:15,1641334872,5/22/2015 14:46:37,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],therapy,none,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:48:57,1641335834,5/22/2015 14:45:59,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS] [MANIFESTATION],"[TREATS]
[MANIFESTATION]",long term anticoagulation therapy Any stroke (ischemic or hemorrhagic),n/a,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:57:09,1641341154,5/22/2015 14:56:24,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],therapy,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:59:52,1641342979,5/22/2015 14:59:29,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 14:59:55,1641343005,5/22/2015 14:59:20,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[TREATS],[TREATS],Fixed dose,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 15:06:53,1641347046,5/22/2015 15:05:51,false,clixsense,1,30544555,USA,TX,Longview,208.180.9.42,[SYMPTOM] [SIDE_EFFECT] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",nonvalvular anticoagulation WARFARIN,n/a,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 15:39:25,1641367188,5/22/2015 15:37:41,false,neodev,1,31294288,USA,IL,Chicago,67.212.188.11,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",requiring long term anticoagulation therapy,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 15:41:06,1641368324,5/22/2015 15:40:41,false,elite,1,31883685,GBR,H2,Accrington,80.47.186.28,[TREATS],[TREATS],or,n/a,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919684,5/22/2015 15:57:08,1641379687,5/22/2015 15:56:31,false,clixsense,1,30681826,GBR,I3,Rochester,86.163.150.232,[TREATS],[TREATS],dose therapy,N/A,378,273,-1,416,281,TWrex-cause,803724-FS1,Fixed dose oral ximelagatran vs adjusted dose warfarin in nonvalvular atrial fibrillation requiring long term anticoagulation therapy at mean 20 months +  Outcomes                                 Event rate per     Difference patient y          (95% CI) Ximelagatran       WARFARIN Any stroke (ischemic or hemorrhagic)   1.6%             1.2%         0.45% ( 0.13 to 1.0) ++ or SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION                  1.0%             1.4%          0.4% { 0.9 to 0.2 +++.,SYSTEMIC EMBOLISM MYOCARDIAL INFARCTION,WARFARIN
724919685,5/22/2015 10:36:59,1641189381,5/22/2015 10:36:46,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[TREATS],[TREATS],the treatment,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:38:11,1641190137,5/22/2015 10:37:56,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF],[PART_OF],of,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:41:16,1641192032,5/22/2015 10:40:36,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],in the treatment of,n/a,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:42:14,1641192665,5/22/2015 10:41:58,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[TREATS],[TREATS],in the treatment of,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:46:51,1641195573,5/22/2015 10:46:29,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[TREATS],[TREATS],the treatment of,N/a,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:47:08,1641195772,5/22/2015 10:46:57,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[TREATS],[TREATS],treatment,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:47:55,1641196195,5/22/2015 10:47:13,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:49:29,1641197041,5/22/2015 10:49:19,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:58:11,1641202450,5/22/2015 10:57:42,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],Troisfontaines B et al. Moclobemide vsCLOMIPRAMINE in the treatment of DEPRESSION:,n/a,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 10:59:33,1641203147,5/22/2015 10:59:03,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [IS_A] [PART_OF],"[TREATS]
[IS_A]
[PART_OF]",treatment of a,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 11:25:30,1641218730,5/22/2015 11:25:08,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[PART_OF],[PART_OF],of,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 11:26:22,1641219215,5/22/2015 11:25:51,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],DEPRESSION:,N/A,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 12:43:03,1641266687,5/22/2015 12:41:25,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],vsCLOMIPRAMINE in treatment of DEPRESSION:,na,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 12:45:47,1641268367,5/22/2015 12:45:26,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treatment,na,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919685,5/22/2015 12:50:19,1641270993,5/22/2015 12:49:58,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],the treatment of,n/a,108,75,-1,117,87,TWrex-cause,803967-FS1,"Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11  1163) vsCLOMIPRAMINE in the treatment of DEPRESSION: a double blind multicenter study in Belgium.",DEPRESSION,CLOMIPRAMINE
724919686,5/22/2015 13:28:06,1641295490,5/22/2015 13:27:30,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],Effects,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 13:29:39,1641296474,5/22/2015 13:28:44,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],placebo controlled study.,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 13:34:06,1641299012,5/22/2015 13:33:50,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Effects of placebo controlled study.,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 13:37:15,1641300912,5/22/2015 13:35:59,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Effects of,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 13:46:27,1641306463,5/22/2015 13:45:42,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],Effects of,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:12:18,1641313884,5/22/2015 14:11:28,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],Effects of ORAL PROPAFENONE ADMINISTRATION before cardioversion of CHRONIC ATRIAL FIBRILLATION:,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:14:27,1641315363,5/22/2015 14:14:01,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],Effects of,n/a,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:30:41,1641324999,5/22/2015 14:28:12,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Effects of before,n/a,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:32:15,1641325904,5/22/2015 14:32:04,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[CAUSES],[CAUSES],Effects,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:32:37,1641326158,5/22/2015 14:31:55,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[OTHER],[OTHER],before,n/a,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:33:40,1641326641,5/22/2015 14:32:04,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[OTHER],[OTHER],Effects of before electrical cardioversion of CHRONIC,n/a,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:36:47,1641328722,5/22/2015 14:36:16,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled,n/a,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:37:24,1641329053,5/22/2015 14:36:30,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],before,none,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:38:13,1641329437,5/22/2015 14:37:57,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919686,5/22/2015 14:50:06,1641336513,5/22/2015 14:49:26,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],Effects of,N/A,116,49,-1,142,80,TWrex-cause,800857-FS1,"Bianconi L, Mennuni M, Lukic V et al. Effects of ORAL PROPAFENONE ADMINISTRATION before electrical cardioversion of CHRONIC ATRIAL FIBRILLATION: a placebo controlled study.",CHRONIC ATRIAL FIBRILLATION,ORAL PROPAFENONE ADMINISTRATION
724919687,5/22/2015 08:37:40,1641126562,5/22/2015 08:37:10,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[CONTRAINDICATES],[CONTRAINDICATES],no longer used for treatment of,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 08:38:35,1641126980,5/22/2015 08:37:50,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[OTHER],[OTHER],no longer used for treatment,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 08:38:38,1641127006,5/22/2015 08:38:22,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treatment,n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 08:45:37,1641130163,5/22/2015 08:44:33,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:08:09,1641141512,5/22/2015 09:07:53,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treatment,-,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:19:24,1641147304,5/22/2015 09:19:12,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treatment,n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:25:47,1641150432,5/22/2015 09:24:52,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:40:40,1641157625,5/22/2015 09:39:10,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS] [CONTRAINDICATES],"[TREATS]
[CONTRAINDICATES]",is not approved by the FDA for treatment of,n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:43:51,1641159483,5/22/2015 09:42:58,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[OTHER],[OTHER],"PLICAMYCIN is no longer used for treatment of ACUTE HYPERCA<span id=""transmark""></span>LCEMIA",n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:46:21,1641160617,5/22/2015 09:46:08,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 09:57:49,1641166582,5/22/2015 09:57:35,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 10:08:16,1641172608,5/22/2015 10:08:03,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treatment,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 10:10:36,1641173959,5/22/2015 10:09:43,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]
[PART_OF]",is by is of,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 10:12:54,1641175310,5/22/2015 10:11:14,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[OTHER],[OTHER],no longer used for treatment,N/A,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919687,5/22/2015 10:13:24,1641175529,5/22/2015 10:13:00,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[CONTRAINDICATES],[CONTRAINDICATES],no longer used for treatment,n/a,158,81,-1,176,91,TWrex-cause,804817-FS1,"Comments: • Despite the fact that it provides marked reduction in serum calcium, PLICAMYCIN is not approved by the FDA and is no longer used for treatment of ACUTE HYPERCALCEMIA",ACUTE HYPERCALCEMIA,PLICAMYCIN
724919688,5/22/2015 08:34:52,1641125326,5/22/2015 08:34:25,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[SYMPTOM],[SYMPTOM],frequent presenting symptom,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 08:34:58,1641125363,5/22/2015 08:34:34,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[SYMPTOM],[SYMPTOM],presenting symptom,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 08:36:51,1641126190,5/22/2015 08:36:15,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presenting symptom,n/a,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 08:39:28,1641127385,5/22/2015 08:38:36,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[SYMPTOM],[SYMPTOM],POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,n/a,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:05:53,1641140405,5/22/2015 09:05:28,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SYMPTOM],[SYMPTOM],symptom,-,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:17:21,1641146082,5/22/2015 09:16:32,false,neodev,1,30627835,GBR,H9,London,5.81.27.94,[SYMPTOM],[SYMPTOM],symptom of,NA,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:17:31,1641146228,5/22/2015 09:17:14,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SYMPTOM],[SYMPTOM],symptom,n/a,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:17:35,1641146269,5/22/2015 09:17:18,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SYMPTOM],[SYMPTOM],symptom,NA,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:32:56,1641153943,5/22/2015 09:31:57,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[SYMPTOM],[SYMPTOM],the most frequent presenting symptom of,n/a,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:38:52,1641156708,5/22/2015 09:36:33,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]","POSTMENOPAUSAL BLEEDING is symptom of ENDOMETRIAL CARC<span id=""transmark""></span>INOMA",n/a,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:44:30,1641159712,5/22/2015 09:44:14,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SYMPTOM],[SYMPTOM],symptom,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 09:55:59,1641165443,5/22/2015 09:55:43,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],presenting,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 10:01:22,1641168659,5/22/2015 10:00:17,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[SYMPTOM],[SYMPTOM],symptom of,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 10:05:42,1641171189,5/22/2015 10:04:59,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [SYMPTOM] [PART_OF],"[SYMPTOM]
[IS_A]
[PART_OF]",is symptom of,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919688,5/22/2015 10:06:35,1641171616,5/22/2015 10:06:17,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[SYMPTOM],[SYMPTOM],symptom,N/A,12,79,1,34,100,TWrex-cause,812838-FS1,Evidence: • POSTMENOPAUSAL BLEEDING is the most frequent presenting symptom of ENDOMETRIAL CARCINOMA ( 35.,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
724919689,5/22/2015 13:34:01,1641298952,5/22/2015 13:32:54,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],extrathoracic disseminated,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 13:37:27,1641301042,5/22/2015 13:36:44,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[OTHER],[OTHER],or,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 13:37:51,1641301328,5/22/2015 13:36:57,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],1 mg/kg daily.,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 13:45:48,1641306001,5/22/2015 13:44:32,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],in 0.7 1 mg/kg daily.,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:06:48,1641310078,5/22/2015 14:06:22,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],infected with disseminated,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:17:36,1641317061,5/22/2015 14:17:12,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:36:17,1641328352,5/22/2015 14:35:33,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[OTHER],[OTHER],infected with,n/a,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:37:30,1641329121,5/22/2015 14:36:35,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],Conventional AMPHOTERICIN B in HIV infected adolescents with COCCIDIOIDOMYCOSIS:,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:39:45,1641330510,5/22/2015 14:38:45,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],with daily.,n/a,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:40:07,1641330759,5/22/2015 14:39:54,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:41:05,1641331236,5/22/2015 14:40:26,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[TREATS],[TREATS],diffuse,n/a,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:41:32,1641331505,5/22/2015 14:40:26,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS],[TREATS],with diffuse pulmonary or extrathoracic disseminated,n/a,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:43:07,1641332508,5/22/2015 14:41:26,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],disseminated,none,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:53:04,1641338342,5/22/2015 14:52:31,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],0.7 1 mg/kg daily.,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919689,5/22/2015 14:55:50,1641340241,5/22/2015 14:55:23,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,114,18,-1,131,32,TWrex-cause,803451-FS1,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
724919690,5/22/2015 10:24:11,1641181539,5/22/2015 10:23:58,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[PREVENTS],[PREVENTS],prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:33:44,1641187261,5/22/2015 10:33:23,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of a of,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:34:04,1641187422,5/22/2015 10:33:51,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[PREVENTS],[PREVENTS],prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:35:56,1641188562,5/22/2015 10:35:31,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[PREVENTS],[PREVENTS],will prevent,n/a,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:36:30,1641188917,5/22/2015 10:36:05,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[PREVENTS],[PREVENTS],will prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:38:15,1641190196,5/22/2015 10:37:01,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PREVENTS],[PREVENTS],will prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:41:48,1641192417,5/22/2015 10:41:18,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[PREVENTS],[PREVENTS],will prevent,N/a,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:43:19,1641193396,5/22/2015 10:43:07,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[PREVENTS],[PREVENTS],prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:46:40,1641195493,5/22/2015 10:46:28,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],prevent,n/a,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:52:25,1641198951,5/22/2015 10:51:22,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[PREVENTS],[PREVENTS],EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,n/a,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 10:52:42,1641199142,5/22/2015 10:52:02,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of a with,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 11:14:02,1641212054,5/22/2015 11:13:11,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[PREVENTS],[PREVENTS],prevent,"Directly states ""prevent""",144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 11:20:40,1641215810,5/22/2015 11:19:15,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],'PURSUIT like' MI,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 11:20:42,1641215814,5/22/2015 11:20:18,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[PART_OF],[PART_OF],of,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919690,5/22/2015 11:57:09,1641237403,5/22/2015 11:55:46,false,neodev,1.0,11001780,AUS,07,Elwood,14.201.215.31,[PREVENTS],[PREVENTS],prevent,N/A,144,101,-1,145,113,TWrex-cause,804663-FS1,The findings of this study can be summarized in a more pragmatic way: Approximately $38 000 worth of EPTIFIBATIDE will prevent 1 'PURSUIT like' MI in aggressively managed patients with high risk acute coronary syndrome,MI,EPTIFIBATIDE
724919691,5/22/2015 10:37:18,1641189586,5/22/2015 10:37:01,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],caused,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:38:32,1641190297,5/22/2015 10:38:15,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",Treatment of caused by,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:41:49,1641192427,5/22/2015 10:41:17,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],Treatment of,n/a,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:42:41,1641192934,5/22/2015 10:42:15,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],caused by,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:47:18,1641195879,5/22/2015 10:46:52,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],infections caused by,N/a,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:47:22,1641195936,5/22/2015 10:47:10,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],caused,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:48:58,1641196749,5/22/2015 10:47:58,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],Treatment of infections,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:49:42,1641197194,5/22/2015 10:49:30,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],Treatment,n/a,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 10:58:40,1641202650,5/22/2015 10:58:11,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",4 5 6 9 NOCARDIA INFECTIONS Treatment of infections caused by NOCARDIA,n/a,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 11:00:02,1641203389,5/22/2015 10:59:37,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",Treatment of caused by,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 11:26:02,1641219011,5/22/2015 11:25:45,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS] [PART_OF] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[PART_OF]",Treatment of caused by,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 11:26:46,1641219444,5/22/2015 11:26:23,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[CAUSES],[CAUSES],NOCARDIA,N/A,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 12:44:08,1641267398,5/22/2015 12:43:03,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],NOCARDIA INFECTIONS caused by NOCARDIA,na,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 12:46:03,1641268506,5/22/2015 12:45:49,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],Treatment,na,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919691,5/22/2015 12:50:46,1641271212,5/22/2015 12:50:20,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",Treatment of infections caused by,n/a,21,21,1,39,29,TWrex-cause,811473-FS1,"4 ,   5 ,   6 ,   9  NOCARDIA INFECTIONS  Treatment of infections caused by  NOCARDIA    +.",NOCARDIA INFECTIONS,NOCARDIA
724919692,5/22/2015 10:36:27,1641188868,5/22/2015 10:36:14,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[PREVENTS],[PREVENTS],anterior,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:37:28,1641189668,5/22/2015 10:37:04,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with with or with or,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:40:16,1641191362,5/22/2015 10:39:22,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[NONE],[NONE],n/a,two conditions are being compared,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:41:42,1641192342,5/22/2015 10:40:49,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:46:00,1641195147,5/22/2015 10:45:31,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[NONE],[NONE],N/a,Two unrelated terms.,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:46:02,1641195148,5/22/2015 10:44:25,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[NONE],[NONE],N/A,they aren't related to each other,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:46:38,1641195474,5/22/2015 10:46:23,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[SYMPTOM],[SYMPTOM],skin lesions,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:49:03,1641196813,5/22/2015 10:48:47,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],with,n/a,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:57:09,1641201795,5/22/2015 10:56:28,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],Consider topical steroids in patients with mild SARCOIDOSIS,n/a,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 10:58:22,1641202554,5/22/2015 10:57:47,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with with or with,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 11:24:30,1641218217,5/22/2015 11:23:59,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with with or with or,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 11:25:32,1641218744,5/22/2015 11:24:26,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],COUGH,N/A,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 12:39:19,1641264433,5/22/2015 12:38:35,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Consider patients with mild SARCOIDOSIS or COUGH,na,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 12:45:00,1641267916,5/22/2015 12:44:08,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[NONE],[NONE],n/a,no relation,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919692,5/22/2015 12:48:02,1641269549,5/22/2015 12:45:23,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],Consider topical steroids and inhaled steroids,n/a,157,56,1,161,67,TWrex-cause,814620-FS1,B]  7.1 Consider topical steroids in patients with mild SARCOIDOSIS with skin lesions or anterior uveitis and inhaled steroids in those with nasal polyps or COUGH,COUGH,SARCOIDOSIS
724919693,5/22/2015 10:24:40,1641181794,5/22/2015 10:24:28,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:34:39,1641187772,5/22/2015 10:34:24,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:34:51,1641187966,5/22/2015 10:34:30,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",There of with,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:36:38,1641188989,5/22/2015 10:36:18,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may be associated with,n/a,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:38:30,1641190277,5/22/2015 10:36:51,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:39:58,1641191192,5/22/2015 10:39:06,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:42:38,1641192926,5/22/2015 10:42:12,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[ASSOCIATED_WITH],[ASSOCIATED_WITH],that may be associated with,N/a,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:45:08,1641194519,5/22/2015 10:43:35,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:47:03,1641195696,5/22/2015 10:46:53,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:53:17,1641199508,5/22/2015 10:52:50,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS,n/a,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 10:54:11,1641199925,5/22/2015 10:53:38,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 11:15:18,1641212837,5/22/2015 11:14:42,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,"Directly states ""associated with""",46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 11:21:45,1641216461,5/22/2015 11:21:20,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 11:21:51,1641216503,5/22/2015 11:21:02,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],NONMENSTRUAL STAPH TSS,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919693,5/22/2015 11:59:09,1641238465,5/22/2015 11:57:18,false,prodege,1,12656479,CAN,NB,Fredericton,198.164.157.90,[PREVENTS],[PREVENTS],associated,N/A,46,100,1,70,122,TWrex-cause,810145-FS1,Comments: • There are many different types of STAPHYLOCOCCAL INFECTIONS that may be associated with NONMENSTRUAL STAPH TSS and thus strategies to prevent cases are difficult at best.,STAPHYLOCOCCAL INFECTIONS,NONMENSTRUAL STAPH TSS
724919694,5/22/2015 13:37:27,1641301036,5/22/2015 13:36:34,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],treatment,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 13:38:32,1641301775,5/22/2015 13:38:16,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],intensive treatment of,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 13:48:41,1641307720,5/22/2015 13:47:19,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:08:36,1641310795,5/22/2015 14:07:59,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],treatment with,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:18:33,1641317671,5/22/2015 14:18:17,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],treatment of,n,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:36:57,1641328817,5/22/2015 14:36:43,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],treatment,n/a,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:39:51,1641330589,5/22/2015 14:39:10,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],Long term treatment of TYPE 1 DIABETES with short ACTING INSULIN ANALOG LISPRO,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:40:48,1641331095,5/22/2015 14:40:37,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:41:30,1641331490,5/22/2015 14:40:56,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],treatment of,n/a,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:42:12,1641331868,5/22/2015 14:41:39,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[TREATS],[TREATS],treatment,n/a,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:43:09,1641332522,5/22/2015 14:42:26,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS],[TREATS],intensive treatment with the ACTING INSULIN,n/a,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:44:14,1641333174,5/22/2015 14:43:42,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treatment,none,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:53:51,1641338851,5/22/2015 14:53:30,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],Long term intensive treatment,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:57:07,1641341115,5/22/2015 14:56:45,false,bitcoinget,1.0,21743413,USA,WA,Lynnwood,67.183.5.219,[TREATS],[TREATS],Long term intensive treatment of,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919694,5/22/2015 14:58:00,1641341757,5/22/2015 14:57:48,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,75,106,-1,89,134,TWrex-cause,800069-FS1,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
724919695,5/22/2015 12:59:23,1641276494,5/22/2015 12:58:23,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],RALOXIFENE therapy for treatment of POSTMENOPAUSAL OSTEOPOROSIS,na,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:09:51,1641283148,5/22/2015 13:09:24,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],therapy for treatment prevention),N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:19:07,1641289424,5/22/2015 13:18:30,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment (and prevention) of,N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:22:23,1641291618,5/22/2015 13:22:04,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment (and prevention),N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:24:53,1641293433,5/22/2015 13:23:15,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:26:31,1641294482,5/22/2015 13:26:18,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment (and prevention),N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:30:42,1641297019,5/22/2015 13:28:39,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [PREVENTS] [NONE],"[TREATS]
[PREVENTS]
[NONE]",therapy for treatment (and prevention) of,N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:38:01,1641301486,5/22/2015 13:37:28,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",therapy for treatment prevention),N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 13:44:29,1641305296,5/22/2015 13:43:59,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],RALOXIFENE therapy for treatment of POSTMENOPAUSAL OSTEOPOROSIS,N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:09:51,1641311670,5/22/2015 14:09:26,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment (and prevention),n.a,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:20:02,1641318547,5/22/2015 14:19:23,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],for treatment of,n/a,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:21:29,1641319395,5/22/2015 14:21:08,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS],[TREATS],therapy for treatment,n/a,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:26:08,1641322277,5/22/2015 14:25:49,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],for treatment,n/a,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:29:45,1641324394,5/22/2015 14:29:31,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[TREATS],[TREATS],therapy for treatment,N/A,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919695,5/22/2015 14:31:57,1641325753,5/22/2015 14:31:29,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treatment,none,66,13,-1,92,23,TWrex-cause,804306-FS1,7.3 Consider RALOXIFENE therapy for treatment (and prevention) of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RALOXIFENE
724919696,5/22/2015 10:38:38,1641190339,5/22/2015 10:38:23,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],caused,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:42:24,1641192780,5/22/2015 10:41:59,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[TREATS] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]",Treatment of caused by with,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:43:55,1641193782,5/22/2015 10:43:37,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],infections caused by,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:48:18,1641196419,5/22/2015 10:48:04,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],caused,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:49:25,1641196986,5/22/2015 10:49:04,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],Treatment of infections caused by,N/a,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:50:38,1641197748,5/22/2015 10:50:21,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],caused,n/a,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 10:52:27,1641198989,5/22/2015 10:51:35,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],Treatment of infections caused by,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 11:01:18,1641204160,5/22/2015 11:00:47,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",24 CLOSTRIDIUM INFECTIONS Treatment of infections caused by CLOSTRIDIUM PERFRINGENS,n/a,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 11:02:50,1641205153,5/22/2015 11:02:13,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]
[PART_OF]",Treatment of caused by with or,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 11:29:34,1641221070,5/22/2015 11:28:53,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[CAUSES],[CAUSES],CLOSTRIDIUM PERFRINGENS,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 11:36:11,1641225296,5/22/2015 11:35:39,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[ASSOCIATED_WITH]
[PART_OF]",Treatment of caused by with or,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 12:49:19,1641270267,5/22/2015 12:47:23,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",CLOSTRIDIUM INFECTIONS caused by CLOSTRIDIUM PERFRINGENS,na,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 13:04:48,1641279757,5/22/2015 13:04:30,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CAUSES],[CAUSES],caused by,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 13:08:09,1641282044,5/22/2015 13:07:57,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[LOCATION],[LOCATION],CLOSTRIDIUM,vdff,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919696,5/22/2015 13:09:50,1641283137,5/22/2015 13:08:43,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],caused by,N/A,4,63,1,25,86,TWrex-cause,811236-FS1,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
724919697,5/22/2015 13:31:08,1641297259,5/22/2015 13:30:17,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 13:33:06,1641298410,5/22/2015 13:31:59,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 13:35:31,1641299858,5/22/2015 13:35:12,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 13:40:51,1641303195,5/22/2015 13:39:45,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 13:49:13,1641308069,5/22/2015 13:48:24,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[CAUSES],[CAUSES],indicates causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:15:17,1641315811,5/22/2015 14:14:48,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[CAUSES],[CAUSES],PRIMARY VARICELLA INFECTION causes CONGENITAL VARICELLA SYNDROME,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:15:42,1641316072,5/22/2015 14:15:28,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[CAUSES],[CAUSES],causes,n/a,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:32:50,1641326251,5/22/2015 14:32:41,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:34:05,1641326882,5/22/2015 14:33:45,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[CAUSES],[CAUSES],causes,n/a,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:34:21,1641327069,5/22/2015 14:33:19,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[CAUSES],[CAUSES],causes,n/a,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:37:24,1641329036,5/22/2015 14:36:20,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[CAUSES],[CAUSES],causes in to 2% of cases.,n/a,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:39:08,1641330139,5/22/2015 14:38:57,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[CAUSES],[CAUSES],causes,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:39:25,1641330313,5/22/2015 14:39:09,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[CAUSES],[CAUSES],causes,n/a,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:39:49,1641330559,5/22/2015 14:39:04,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CAUSES],[CAUSES],causes,none,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919697,5/22/2015 14:54:17,1641339063,5/22/2015 14:53:51,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[CAUSES],[CAUSES],causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,N/A,44,109,1,70,138,TWrex-cause,810788-FS1,Evidence: • A review article indicates that PRIMARY VARICELLA INFECTION of the mother before 23 weeks causes CONGENITAL VARICELLA SYNDROME in up to 2% of cases.,PRIMARY VARICELLA INFECTION,CONGENITAL VARICELLA SYNDROME
724919698,5/22/2015 10:23:56,1641181365,5/22/2015 10:23:41,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[PREVENTS],[PREVENTS],prevent,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:33:19,1641187029,5/22/2015 10:32:59,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[IS_A],[IS_A],an,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:33:50,1641187271,5/22/2015 10:33:32,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[PREVENTS],[PREVENTS],prevent,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:35:31,1641188324,5/22/2015 10:34:26,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[CONTRAINDICATES],[CONTRAINDICATES],suppression to prevent clinical recurrences,n/a,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:36:04,1641188637,5/22/2015 10:35:37,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[PREVENTS],[PREVENTS],prevent clinical recurrences,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:36:59,1641189377,5/22/2015 10:35:51,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PREVENTS],[PREVENTS],to prevent,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:41:17,1641192039,5/22/2015 10:40:28,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],suppression to prevent clinical recurrences,N/a,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:43:06,1641193211,5/22/2015 10:42:55,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[PREVENTS],[PREVENTS],prevent,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:46:27,1641195391,5/22/2015 10:46:09,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],prevent,n/a,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:51:21,1641198245,5/22/2015 10:50:49,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[PREVENTS],[PREVENTS],prevent clinical recurrences at delivery after GENITAL HERPES in pregnancy:,n/a,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 10:51:58,1641198641,5/22/2015 10:51:25,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A],[IS_A],an,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 11:13:10,1641211550,5/22/2015 11:12:30,false,tremorgames,1.0,31906954,USA,NY,Middletown,74.68.51.54,[PREVENTS],[PREVENTS],prevent,"Directly states ""prevent""",160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 11:19:13,1641215121,5/22/2015 11:18:09,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],clinical recurrences,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 11:20:14,1641215575,5/22/2015 11:19:35,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A],[IS_A],an,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919698,5/22/2015 11:54:06,1641235690,5/22/2015 11:52:44,false,neodev,1.0,11001780,AUS,07,Elwood,14.201.215.31,[PREVENTS],[PREVENTS],prevent,N/A,160,74,-1,173,83,TWrex-cause,804390-FS1,"2]  Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD JrACYCLOVIR suppression to prevent clinical recurrences at delivery after first episode GENITAL HERPES in pregnancy: an open label trial.",GENITAL HERPES,ACYCLOVIR
724919699,5/22/2015 13:01:34,1641277679,5/22/2015 13:01:01,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],alPAROXETINE in treatment of PANIC DISORDER:,na,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:12:21,1641284759,5/22/2015 13:11:51,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],in the treatment of,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:23:42,1641292587,5/22/2015 13:23:01,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],treatment of,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:24:16,1641292931,5/22/2015 13:24:00,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],treatment,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:27:28,1641295166,5/22/2015 13:27:18,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],in the treatment,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:29:33,1641296383,5/22/2015 13:28:59,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:38:56,1641302043,5/22/2015 13:36:31,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",treatment of,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:40:42,1641303093,5/22/2015 13:40:09,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],in the treatment of,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 13:47:39,1641307166,5/22/2015 13:47:07,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],alPAROXETINE in treatment of PANIC DISORDER:,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:11:49,1641313585,5/22/2015 14:11:35,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],treatment of,n/a,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:23:26,1641320689,5/22/2015 14:22:49,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],treatment of,n/a,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:24:23,1641321193,5/22/2015 14:23:54,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[TREATS],[TREATS],in the treatment of PANIC,n/a,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:29:05,1641324091,5/22/2015 14:27:56,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],treatment of,n/a,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:30:40,1641325001,5/22/2015 14:30:27,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[TREATS],[TREATS],treatment,N/A,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919699,5/22/2015 14:33:53,1641326790,5/22/2015 14:33:36,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treatment,none,74,43,-1,87,53,TWrex-cause,800191-FS1,"Oehrberg S, Christiansen PE, Behnke K et alPAROXETINE in the treatment of PANIC DISORDER: a randomised, double blind, placebo controlled study.",PANIC DISORDER,PAROXETINE
724919700,5/22/2015 13:01:00,1641277396,5/22/2015 13:00:21,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],No evidence MILRINONE associated with CHF,na,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:11:50,1641284546,5/22/2015 13:10:45,false,prodege,1,14848125,GBR,U8,Edinburgh,86.149.215.103,[NONE],[NONE],N/A,iT has been used to treat but found not to work effectively,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:23:00,1641292155,5/22/2015 13:21:23,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.121.10,[OTHER],[OTHER],No evidence,NO EVIDENCE - so the there is no positive relation between the two and it is NOT suggested as a contra indication either.,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:23:58,1641292764,5/22/2015 13:23:23,false,clixsense,1,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],decreases mortality,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:27:17,1641295037,5/22/2015 13:27:00,false,elite,1,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],decreases mortality associated with,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:28:58,1641296083,5/22/2015 13:27:24,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],No evidence decreases mortality associated,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:36:28,1641300398,5/22/2015 13:33:50,false,clixsense,1,6363498,USA,GA,Fort Valley,23.125.3.6,[OTHER] [ASSOCIATED_WITH] [NONE],"[ASSOCIATED_WITH]
[OTHER]
[NONE]","No evidence to date that, decreases mortality associated",N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:40:05,1641302750,5/22/2015 13:39:13,false,neodev,1,21515166,NLD,11,Den Haag,83.81.176.56,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 13:47:07,1641306819,5/22/2015 13:45:25,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],No evidence that MILRINONE decreases mortality with CHF,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:11:34,1641313443,5/22/2015 14:10:41,false,clixsense,1,24329110,USA,"","",65.196.181.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],No evidence,n/a,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:22:48,1641320296,5/22/2015 14:21:03,false,neodev,1,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",decreases,n/a,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:23:53,1641320907,5/22/2015 14:22:47,false,neodev,1,32216655,NLD,07,Amsterdam,145.100.72.168,[ASSOCIATED_WITH],[ASSOCIATED_WITH],decreases mortality associated with,n/a,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:27:54,1641323373,5/22/2015 14:27:19,false,instagc,1,25990856,USA,NV,Las Vegas,98.160.220.169,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:30:26,1641324786,5/22/2015 14:30:11,false,tremorgames,1,17272211,USA,PA,Havertown,173.49.116.92,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919700,5/22/2015 14:33:35,1641326593,5/22/2015 14:32:48,false,clixsense,1,11106820,USA,MA,Taunton,173.48.52.95,[OTHER],[OTHER],decreases mortality,none,116,70,-1,118,79,TWrex-cause,800593-FS1,"1 ,   3 ,   13 ,   15 ,   16 ,   22 ,   23   No evidence to date that MILRINONE decreases mortality associated with CHF",CHF,MILRINONE
724919701,5/22/2015 10:22:35,1641180520,5/22/2015 10:22:22,false,elite,1,31227441,USA,IL,Chicago,173.193.202.116,[CAUSES],[CAUSES],causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:31:16,1641185693,5/22/2015 10:30:53,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[IS_A] [CAUSES],"[CAUSES]
[IS_A]",is causes causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:31:35,1641185889,5/22/2015 10:31:21,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:31:51,1641186052,5/22/2015 10:31:16,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],which causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:31:57,1641186116,5/22/2015 10:31:22,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[CAUSES],[CAUSES],which causes,n/a,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:32:04,1641186185,5/22/2015 10:31:45,false,points4rewards,1,20113482,USA,OR,Portland,67.213.218.72,[CAUSES],[CAUSES],causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:33:09,1641186895,5/22/2015 10:31:51,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[CAUSES],[CAUSES],which causes,n/a,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:34:10,1641187455,5/22/2015 10:33:25,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:38:04,1641190054,5/22/2015 10:37:40,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[CAUSES],[CAUSES],which causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:41:59,1641192507,5/22/2015 10:41:42,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:44:22,1641194047,5/22/2015 10:44:09,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],causes,n/a,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:47:47,1641196117,5/22/2015 10:47:16,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A] [CAUSES],"[CAUSES]
[IS_A]",is causes causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 10:48:46,1641196654,5/22/2015 10:48:14,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],ANAPLASMA PHAGOCYTOPHILA causes HUMAN GRANULOCYTIC EHRLICHIOSIS,n/a,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 11:07:27,1641207975,5/22/2015 11:04:49,false,tremorgames,1,31906954,USA,NY,Middletown,74.68.51.54,[CAUSES],[CAUSES],causes,"It directly states that it ""causes""",77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919701,5/22/2015 11:15:42,1641213104,5/22/2015 11:14:36,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[IS_A] [ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]
[IS_A]",is causes which causes,N/A,77,37,1,107,61,TWrex-cause,810278-FS1,"I. scapularis  is also a vector for  ANAPLASMA PHAGOCYTOPHILA , which causes HUMAN GRANULOCYTIC EHRLICHIOSIS [  see 7:XVII Infections Due to   Rickettsia, Ehrlichia,  and  Coxiella], and  Babesia microti , which causes babesiosis [  see 7:XXXIV Protozoan Infections.",HUMAN GRANULOCYTIC EHRLICHIOSIS,ANAPLASMA PHAGOCYTOPHILA
724919702,5/22/2015 13:32:11,1641297924,5/22/2015 13:31:53,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],effective treatment,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 13:36:14,1641300309,5/22/2015 13:35:50,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],an effective treatment,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 13:36:18,1641300333,5/22/2015 13:34:33,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],treatment in,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 13:43:12,1641304509,5/22/2015 13:42:06,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 13:50:54,1641308973,5/22/2015 13:50:24,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],is treatment in,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:16:35,1641316510,5/22/2015 14:16:12,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],an effective treatment,n,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:34:54,1641327543,5/22/2015 14:34:25,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],treatment,n/a,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:35:26,1641327900,5/22/2015 14:34:48,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],alBUDESONIDE effective treatment children with PERENNIAL ALLERGIC RHINITIS,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:36:33,1641328565,5/22/2015 14:36:01,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],is an effective treatment,n/a,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:39:19,1641330275,5/22/2015 14:38:45,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",spray is an effective treatment in children,n/a,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:39:34,1641330408,5/22/2015 14:39:22,false,sharecashgpt,1.0,28627999,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:39:55,1641330605,5/22/2015 14:39:42,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.125.145.37,[TREATS],[TREATS],treatment,n/a,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:40:37,1641330979,5/22/2015 14:40:18,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treatment,none,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:51:53,1641337624,5/22/2015 14:51:34,false,clixsense,1.0,23197581,NLD,11,Den Haag,82.217.5.55,[TREATS],[TREATS],is an effective treatment,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919702,5/22/2015 14:55:25,1641339924,5/22/2015 14:54:40,false,clixsense,1,12843982,AUS,08,Perth,180.216.79.226,[TREATS],[TREATS],alBUDESONIDE treatment PERENNIAL ALLERGIC RHINITIS,N/A,117,43,-1,143,53,TWrex-cause,803746-FS1,"Fokkens WJ, Cserhati E, dos Santos JM et alBUDESONIDE aqueous nasal spray is an effective treatment in children with PERENNIAL ALLERGIC RHINITIS with an onset of action within 12 hours.",PERENNIAL ALLERGIC RHINITIS,BUDESONIDE
724919703,5/22/2015 08:40:30,1641127914,5/22/2015 08:40:09,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 08:41:09,1641128186,5/22/2015 08:40:54,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treatment,n/a,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 08:52:09,1641133371,5/22/2015 08:51:24,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER,n/a,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 08:57:44,1641136114,5/22/2015 08:57:15,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 09:12:04,1641143362,5/22/2015 09:11:51,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treatment,-,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 09:35:21,1641154975,5/22/2015 09:34:25,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treatment,NA,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 09:49:50,1641162302,5/22/2015 09:49:30,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 09:50:11,1641162439,5/22/2015 09:49:41,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"ALPRAZOLAM treatment of PANIC D<span id=""transmark""></span>ISORDER",n/a,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 09:59:46,1641167659,5/22/2015 09:59:33,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:09:50,1641173521,5/22/2015 10:09:39,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:14:54,1641176448,5/22/2015 10:14:23,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:18:26,1641178147,5/22/2015 10:18:12,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[TREATS],[TREATS],group treatment,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:20:58,1641179550,5/22/2015 10:20:12,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],treatment of,N/A,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:21:55,1641180159,5/22/2015 10:21:13,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treatment of,n/a,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919703,5/22/2015 10:22:42,1641180606,5/22/2015 10:21:21,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[TREATS],[TREATS],treatment of,n/a,131,86,-1,144,96,TWrex-cause,800918-FS1,"Nagy LM, Krystal JH, Woods SW et al. Clinical and medication outcome after short term ALPRAZOLAM and behavioral group treatment of PANIC DISORDER",PANIC DISORDER,ALPRAZOLAM
724919704,5/22/2015 13:09:02,1641282587,5/22/2015 13:08:14,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],increased risk of malformations in infants of mothers who received MEPROBAMATE during PREGNANCY,na,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:13:44,1641285766,5/22/2015 13:13:17,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[CONTRAINDICATES],[CONTRAINDICATES],increased risk,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:25:41,1641293939,5/22/2015 13:25:19,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[CAUSES] [CONTRAINDICATES],"[CAUSES]
[CONTRAINDICATES]",increased risk of,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:26:35,1641294496,5/22/2015 13:25:17,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[CONTRAINDICATES],[CONTRAINDICATES],increased risk received,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:28:34,1641295827,5/22/2015 13:28:16,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],who received,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:33:15,1641298514,5/22/2015 13:31:50,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CONTRAINDICATES],[CONTRAINDICATES],increased risk,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:43:44,1641304754,5/22/2015 13:42:26,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],received,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:45:32,1641305794,5/22/2015 13:43:41,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [SIDE_EFFECT] [NONE],"[CAUSES]
[SIDE_EFFECT]
[NONE]",increased risk of,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 13:51:58,1641309522,5/22/2015 13:50:48,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[OTHER],[OTHER],increased risk who received MEPROBAMATE during PREGNANCY,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:13:14,1641314568,5/22/2015 14:12:49,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[CONTRAINDICATES],[CONTRAINDICATES],increased risk,n/a,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:26:08,1641322279,5/22/2015 14:25:26,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[SIDE_EFFECT],[SIDE_EFFECT],increased risk of,n/a,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:30:51,1641325109,5/22/2015 14:30:30,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[PART_OF],[PART_OF],during the first trimester,n/a,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:30:59,1641325168,5/22/2015 14:30:33,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[MANIFESTATION],[MANIFESTATION],increased risk of congenital malformations during the first trimester,n/a,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:31:32,1641325588,5/22/2015 14:31:13,false,tremorgames,1.0,17272211,USA,PA,Havertown,173.49.116.92,[SYMPTOM],[SYMPTOM],increased risk of,N/A,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919704,5/22/2015 14:35:37,1641328031,5/22/2015 14:35:09,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CONTRAINDICATES],[CONTRAINDICATES],increased risk,none,232,190,-1,240,201,TWrex-cause,803077-FS1,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
724919705,5/22/2015 08:41:27,1641128362,5/22/2015 08:41:13,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present with,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 08:42:22,1641128711,5/22/2015 08:42:10,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present with,n/a,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 08:55:23,1641134869,5/22/2015 08:54:30,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,n/a,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 08:59:54,1641137247,5/22/2015 08:59:28,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[SYMPTOM],[SYMPTOM],present with,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 09:13:15,1641143983,5/22/2015 09:12:47,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[SYMPTOM],[SYMPTOM],present,-,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 09:38:31,1641156552,5/22/2015 09:37:39,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[SYMPTOM],[SYMPTOM],present,NA,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 09:50:48,1641162780,5/22/2015 09:50:35,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[SYMPTOM],[SYMPTOM],present,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 09:52:41,1641163851,5/22/2015 09:52:11,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]","MYOTONIA CONGENITA present with MUSCLE HYPERT<span id=""transmark""></span>ROPHY",n/a,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:00:36,1641168107,5/22/2015 10:00:18,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:10:36,1641173950,5/22/2015 10:10:24,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[SYMPTOM],[SYMPTOM],present,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:16:36,1641177249,5/22/2015 10:16:14,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with with with,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:19:15,1641178714,5/22/2015 10:19:02,false,elite,1.0,31227441,USA,IL,Chicago,173.193.202.116,[SYMPTOM],[SYMPTOM],present,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:24:11,1641181544,5/22/2015 10:23:29,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],often with,N/A,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:24:35,1641181788,5/22/2015 10:24:00,false,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.92.227,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",present with,n/a,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919705,5/22/2015 10:25:05,1641182028,5/22/2015 10:24:12,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with with,n/a,70,14,1,87,32,TWrex-cause,813670-FS1,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
724919706,5/22/2015 10:38:21,1641190222,5/22/2015 10:38:02,false,elite,1.0,31502056,USA,VA,Manassas,198.7.58.103,[CAUSES],[CAUSES],caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:41:54,1641192458,5/22/2015 10:41:30,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[CAUSES],[CAUSES],caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:43:37,1641193555,5/22/2015 10:43:15,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[CAUSES],[CAUSES],agent that caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:48:03,1641196284,5/22/2015 10:47:51,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:49:03,1641196807,5/22/2015 10:48:32,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[PART_OF],[PART_OF],was rediscovered as the,N/a,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:50:20,1641197610,5/22/2015 10:50:08,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],caused,n/a,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 10:51:33,1641198340,5/22/2015 10:50:48,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was rediscovered as the,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 11:00:46,1641203831,5/22/2015 11:00:05,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"TATLOCK HEBA, L MICDADEI was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia",n/a,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 11:02:09,1641204731,5/22/2015 11:01:33,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[CAUSES],[CAUSES],caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 11:28:52,1641220576,5/22/2015 11:27:49,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[PREVENTS],[PREVENTS],pneumonia,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 11:35:36,1641224938,5/22/2015 11:35:16,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[CAUSES],[CAUSES],caused,28630436,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 12:47:22,1641269223,5/22/2015 12:46:38,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[IS_A],[IS_A],L MICDADEI was rediscovered as PITTSBURGH PNEUMONIA,na,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 13:04:28,1641279622,5/22/2015 13:03:25,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[OTHER],[OTHER],rediscovered,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 13:07:55,1641281861,5/22/2015 13:07:40,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],rediscovered,bcvbb,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919706,5/22/2015 13:09:32,1641282925,5/22/2015 13:07:50,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[CAUSES] [NONE],"[CAUSES]
[NONE]",agent that caused,N/A,75,39,1,94,49,TWrex-cause,812582-FS1,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
724919707,5/22/2015 11:39:09,1641226960,5/22/2015 11:38:47,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],HISTOPLASMOSIS,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 11:42:11,1641228751,5/22/2015 11:41:53,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[TREATS],[TREATS],therapy,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 12:56:44,1641274864,5/22/2015 12:56:20,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],FLUCONAZOLE therapy for HISTOPLASMOSIS,na,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:09:05,1641282611,5/22/2015 13:08:50,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[TREATS],[TREATS],therapy for,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:16:35,1641287718,5/22/2015 13:15:30,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[TREATS],[TREATS],therapy for,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:21:07,1641290717,5/22/2015 13:20:55,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[TREATS],[TREATS],therapy,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:21:55,1641291201,5/22/2015 13:20:13,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],therapy,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:25:48,1641294018,5/22/2015 13:25:36,false,elite,1.0,31856422,GBR,C9,Carlisle,92.19.36.179,[TREATS],[TREATS],therapy for,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:26:33,1641294489,5/22/2015 13:23:58,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[TREATS] [NONE],"[TREATS]
[NONE]",therapy for,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:36:05,1641300213,5/22/2015 13:35:28,false,neodev,1.0,21515166,NLD,11,Den Haag,83.81.176.56,[TREATS],[TREATS],therapy,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 13:42:51,1641304383,5/22/2015 13:42:26,false,points4rewards,1.0,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],FLUCONAZOLE therapy for HISTOPLASMOSIS,N/A,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 14:09:06,1641311015,5/22/2015 14:08:41,false,clixsense,1.0,24329110,USA,"","",65.196.181.2,[TREATS],[TREATS],therapy for,n/a,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 14:18:40,1641317776,5/22/2015 14:17:59,false,neodev,1.0,32216655,NLD,07,Amsterdam,145.100.72.168,[PREVENTS],[PREVENTS],therapy for,n/a,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 14:18:50,1641317876,5/22/2015 14:18:05,false,neodev,1.0,27667288,CAN,MB,Brandon,216.36.154.251,[TREATS],[TREATS],therapy for,n/a,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919707,5/22/2015 14:25:28,1641321814,5/22/2015 14:25:10,false,instagc,1.0,25990856,USA,NV,Las Vegas,98.160.220.169,[TREATS],[TREATS],therapy for,n/a,68,44,-1,81,55,TWrex-cause,803595-FS1,"McKinsey DS, Kauffman CA, Pappas PG, et al: FLUCONAZOLE therapy for HISTOPLASMOSIS",HISTOPLASMOSIS,FLUCONAZOLE
724919708,5/22/2015 08:35:40,1641125623,5/22/2015 08:35:15,false,instagc,1.0,30326470,USA,CA,Santee,99.44.37.73,[TREATS],[TREATS],treated with,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 08:35:55,1641125713,5/22/2015 08:35:36,false,prodege,1.0,27934334,GBR,D2,Derby,86.162.35.12,[TREATS],[TREATS],treated with,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 08:37:22,1641126389,5/22/2015 08:37:09,false,instagc,1.0,13581319,USA,IL,Mount Vernon,66.232.166.86,[TREATS],[TREATS],treated,n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 08:41:55,1641128537,5/22/2015 08:40:49,false,clixsense,1.0,10798016,GBR,C7,Coventry,86.24.245.191,[TREATS],[TREATS],TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:06:27,1641140620,5/22/2015 09:06:11,false,cointasker,1.0,21783324,NLD,11,Schiedam,194.13.104.198,[TREATS],[TREATS],treated,-,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:18:19,1641146641,5/22/2015 09:18:06,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treated,n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:20:44,1641147927,5/22/2015 09:19:07,false,prodege,1.0,16878855,CAN,BC,Fort Saint John,216.232.163.142,[TREATS],[TREATS],treated,NA,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:34:40,1641154740,5/22/2015 09:33:52,false,clixsense,1.0,26847653,NLD,03,Warnsveld,213.93.50.164,[TREATS],[TREATS],is treated with a single dose of,n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:40:16,1641157455,5/22/2015 09:39:39,false,clixsense,1.0,22947672,GBR,"","",88.144.127.68,[TREATS],[TREATS],"ORAL CANDIDIASIS i<span id=""transmark""></span>s treated with FLUCONAZOLE",n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:45:04,1641160067,5/22/2015 09:44:51,false,elite,1.0,31501118,USA,IL,Chicago,158.255.213.24,[TREATS],[TREATS],treated,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 09:56:29,1641165796,5/22/2015 09:56:16,false,elite,1.0,31685662,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treated,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 10:07:07,1641171934,5/22/2015 10:06:55,false,elite,1.0,30655282,USA,AZ,Tempe,23.235.227.109,[TREATS],[TREATS],treated,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 10:07:17,1641172052,5/22/2015 10:06:25,false,points4rewards,1.0,20113482,USA,OR,Portland,67.213.218.72,[TREATS],[TREATS],treated with,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 10:07:35,1641172331,5/22/2015 10:06:39,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",is with a of or with or,N/A,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919708,5/22/2015 10:10:32,1641173917,5/22/2015 10:09:51,false,clixsense,1.0,21484973,GBR,L6,Shrewsbury,86.153.186.114,[TREATS],[TREATS],treated,n/a,11,61,-1,26,72,TWrex-cause,800089-FS1,TREATMENT: ORAL CANDIDIASIS is treated with a single dose of FLUCONAZOLE or with clotrimazole lozenges or nystatin oral solution (which must be held in the mouth for several minutes before swallowing) for 14 days.,ORAL CANDIDIASIS,FLUCONAZOLE
724919709,5/22/2015 10:42:57,1641193123,5/22/2015 10:42:27,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",with is with symptoms,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 10:44:15,1641193959,5/22/2015 10:43:56,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",often presents with,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 10:48:32,1641196542,5/22/2015 10:48:19,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 10:49:44,1641197223,5/22/2015 10:49:26,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[MANIFESTATION],[MANIFESTATION],often presents with,N/a,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 10:50:52,1641197923,5/22/2015 10:50:39,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 10:53:20,1641199529,5/22/2015 10:52:29,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],often presents with RAPID ONSET VIRILIZATION;,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 11:01:37,1641204361,5/22/2015 11:01:19,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION;,n/a,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 11:03:34,1641205584,5/22/2015 11:02:53,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [IS_A] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]",with is with symptoms,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 11:30:35,1641221860,5/22/2015 11:29:35,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[SYMPTOM],[SYMPTOM],"fatigue, weakness, weight loss.",N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 11:36:36,1641225518,5/22/2015 11:36:13,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[ASSOCIATED_WITH] [IS_A] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]",with is with symptoms,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 12:50:46,1641271216,5/22/2015 12:49:20,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],ADRENAL CARCINOMA presents with RAPID ONSET VIRILIZATION;,na,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 13:05:24,1641280204,5/22/2015 13:04:49,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[SYMPTOM],[SYMPTOM],presents with,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 13:08:21,1641282216,5/22/2015 13:08:11,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[PREVENTS],[PREVENTS],often,dfdf,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 13:10:17,1641283456,5/22/2015 13:09:51,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[SYMPTOM],[SYMPTOM],presents with,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919709,5/22/2015 13:10:43,1641283745,5/22/2015 13:09:34,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[ASSOCIATED_WITH] [NONE],"[ASSOCIATED_WITH]
[NONE]",it is often associated with,N/A,38,0,1,61,17,TWrex-cause,812622-FS1,"ADRENAL CARCINOMA often presents with RAPID ONSET VIRILIZATION; it is often associated with systemic symptoms such as fatigue, weakness, and weight loss.",RAPID ONSET VIRILIZATION,ADRENAL CARCINOMA
724919710,5/22/2015 10:43:44,1641193634,5/22/2015 10:43:22,false,neodev,1.0,28630436,USA,DE,Wilmington,162.223.93.178,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of by of of,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 10:44:50,1641194337,5/22/2015 10:44:31,false,instagc,1.0,13763729,USA,NC,Apex,75.182.91.110,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",marked by,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 10:48:59,1641196778,5/22/2015 10:48:46,false,elite,1.0,30654968,USA,OR,Portland,67.213.218.73,[CAUSES],[CAUSES],marked,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 10:50:40,1641197756,5/22/2015 10:50:04,false,prodege,1.0,22031444,GBR,K6,Southsea,80.44.194.25,[PART_OF],[PART_OF],marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,N/a,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 11:02:30,1641204895,5/22/2015 11:01:55,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[SYMPTOM],[SYMPTOM],Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE,n/a,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 11:04:44,1641206357,5/22/2015 11:04:04,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of by of of,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 11:31:58,1641222879,5/22/2015 11:31:43,false,clixsense,1.0,17950689,GBR,Y9,Tonypandy,92.2.44.79,[TREATS],[TREATS],MUCOUS MEMBRANE,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 11:37:27,1641226052,5/22/2015 11:37:00,false,neodev,1.0,29579905,GBR,"","",5.152.206.71,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of by of of,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 12:52:35,1641272166,5/22/2015 12:51:12,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],NASAL MUCOUS MEMBRANE marked by MUCOUS MEMBRANE,na,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:06:19,1641280821,5/22/2015 13:05:40,false,prodege,1.0,14848125,GBR,U8,Edinburgh,86.149.215.103,[MANIFESTATION],[MANIFESTATION],marked by,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:08:47,1641282426,5/22/2015 13:08:36,false,neodev,1.0,31726043,USA,VA,Manassas,207.244.77.2,[LOCATION],[LOCATION],MUCOUS,vdf,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:11:25,1641284294,5/22/2015 13:10:50,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.121.10,[SYMPTOM],[SYMPTOM],marked by,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:13:40,1641285712,5/22/2015 13:12:25,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[PART_OF],[PART_OF],of the the septum.,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:14:40,1641286361,5/22/2015 13:12:04,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [SYMPTOM],"[SYMPTOM]
[NONE]",marked by,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
724919710,5/22/2015 13:16:20,1641287496,5/22/2015 13:15:20,false,clixsense,1.0,31579138,AUS,02,Hurstville,14.200.129.68,[SYMPTOM],[SYMPTOM],marked by,N/A,20,26,-1,40,41,TWrex-cause,802426-FS1,Inflammation of the NASAL MUCOUS MEMBRANE marked by hypertrophy of the MUCOUS MEMBRANE of the turbinates and the septum.,NASAL MUCOUS MEMBRANE,MUCOUS MEMBRANE
